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1. Summary 
 
The Melanoma Antigen Genes (MAGE) belong to a large family of highly conserved genes, 
sharing an elevated degree of sequence homology. The characteristic feature of MAGE 
proteins is a C-terminal domain present in all the members of the family, termed the MAGE 
homology domain (MHD). Based on their expression pattern MAGE genes are classified in 
MAGE-I and MAGE-II genes. MAGE-I genes expression is restricted to tumor and male 
germ cells, and for this reason they form part of a growing group of genes named Cancer 
Testis Antigens (CTA). Expression of MAGE-I genes seems to be an early event during 
gametogenesis and tumorigenesis, and correlates with genomewide hypomethylation, an 
important event frequently observed in carcinogenesis.  
Since their discovery in 1991, MAGE-I genes were mostly studied for their potential use in 
immunotherapy against cancer or as prognostic markers in tumors. The biological roles that 
these proteins play in tumor development and progression were poorly investigated. 
Moreover, due to their sequence homology, MAGE-I proteins are still considered functionally 
redundant proteins. In the present work, we functionally characterized different MAGE-I 
genes, in particular MageA2 and MageB2 genes, demonstrating their functional specificity. 
We show that MageA2 protein confers wild-type p53 tumor suppressor-sensitive resistance to 
chemotherapeutic drugs, such as etoposide, by recruitment of HDAC3 to p53/MageA2 
complex, thus repressing p53 transactivation function. The mechanism responsible for the 
repressive effect of MageA2, relies on an impaired acetylation of both p53 and histones 
surrounding p53 binding sites by MageA2/HDAC3 complexes. The correlation between 
MAGE-A expression and resistance to apoptosis has been analyzed in short-term melanoma 
cell lines, where combined treatment with etoposide and trichostatin A (an inhibitor of histone 
deacetylases) restores the p53 response and reverts chemoresistance in cells expressing high 
levels of MAGE-A.  
We also present evidence that MageA2 is able to repress PML3-induced p53 activity in a 
specific manner, by affecting PML3 mediated p53 acetylation at the PML3 nuclear bodies 
(PML3-NBs). The relevance of MageA2 expression on PML3 activity has been analyzed in a 
normal cellular context, in which PML3 induces premature senescence, an important barrier 
against cell transformation. In this regard, we demonstrate that MageA2 impairs the 
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senescence response associated to PML3 expression in normal human fibroblast. A possible 
mechanism for the inhibitory effect of MageA2 on PML3 is that MageA2 could interfere with 
PML3 sumoylation. The specificity of MageA2 functions is demonstrated by the fact that, 
despite high level of homology, MageA4 is not recruited to the NBs, it does not affect p53 
activity nor is able to interfere with PML3 induced senescence. 
Finally, we have preliminarily characterized the MageB2 protein, showing that it specifically 
localizes to the nucleolus where it is able to interact with many nucleolar proteins. Nucleolar 
stress induces MageB2 relocalization to the nucleoplasm, a characteristic behavior of 
nucleolar proteins that regulate processes such as rRNA metabolism or RNA processing. 
Moreover, since we observed that MageB2 induces pRb relocalization to the nucleoli and 
increases E2F1 transactivation function, including E2F1-induced rRNA transcription, we 
hypothesize that it could play a positive role in the regulation of cell proliferation. 
Altogether the work presented here consistently supports the notion that, despite the high 
level of sequence homology, there is a clear degree of functional specificity within members 
of the MAGE-I family. Hence, we can hypothesize that different MAGE-I proteins, for 
instance MageA2 and MageB2, could act within different pathways in the regulation of 
complex processes such as apoptosis, proliferation, and senescence. By targeting different 
signal transduction pathways their final outcome could be related to the establishment and 
progression of the tumors where they are expressed.  
In this Thesis, we give a comprehensive view on the functional differences among MAGE-I 
members, focusing on Mage-A and Mage-B members. Implementation of our investigation 
could be the first step leading to understanding of how expression of specific MAGE-I 
members could impact cancer cell behaviour thus prompting the use of MAGE-I genes as 
novel cancer specific targets for the development of new drug-based therapies. 
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2. Introduction 
 
The Melanoma Antigen Genes (MAGE) 
 
MAGE genes belong to a large family of closely related genes characterized by a high degree 
of sequence homology (Fig. A) (Chomez, De Backer et al. 2001). The first human members 
of the MAGE gene family that have been described (now referred as MAGE-I subfamily) are 
expressed in tumor cells but silent in normal adult tissues except in male germ cells and 
placenta. Consequently, MAGE-I genes are considered tumor-specific antigens belonging to 
the Cancer/Testis Antigens (CTA) superfamily (van der Bruggen, Traversari et al. 1991; 
Rogner, Wilke et al. 1995; Chomez, De Backer et al. 2001; Barker and Salehi 2002). Based 
on this findings, MAGE-I proteins have become important targets for cancer immunotherapy 
(Marchand, van Baren et al. 1999; Thurner, Haendle et al. 1999; Kruit, van Ojik et al. 2005). 
However, other members of the family were recently found to be expressed in normal cells 
(now referred as MAGE-II subfamily), indicating that the family is larger and more disparate 
than initially expected (Lucas, Brasseur et al. 1999; Pold, Zhou et al. 1999; Chomez, De 
Backer et al. 2001). Sequence homology analysis has led to the recognition of other members 
and to date more than 60 MAGE genes have been identified and classified in different groups 
and subfamilies (Chomez, De Backer et al. 2001; Xiao and Chen 2004) (Table A). 
 
a) The discovery of tumor specific MAGE proteins 
 
In the last decades great efforts have been devoted to the search for tumor antigens, which 
could be used to direct the cytolytic capacities of the human immune system against cancer 
(Old 1981; Boon and Old 1997). An ideal cancer antigen for immunotherapy should be 
specifically and stably expressed by the tumor, absent from normal tissues, and crucial for 
survival of cancer cells. An important turning point in this search was the adoption of an 
approach called autologous typing, in which cultured tumor and normal cells from a patient 
were used as targets for specific immune recognition by the patient’s own antibodies and T 
cells (Old 1981; Knuth, Danowski et al. 1984).     
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Fig. A: Multiple sequence alignment of selected MAGE type I members, 
showing the high degree of sequence homology shared by these proteins.  
 
 
The first CTA was identified in 1991 through autologous typing and the application of a 
newly developed DNA-cloning methodology for defining the targets of T-cell recognition 
(Van Pel, van der Bruggen et al. 1995). A patient with melanoma who had an unusually 
favorable clinical course was identified as having cytotoxic T cells that recognized autologous 
tumor cells (Knuth, Wolfel et al. 1989). Using this system, the gene encoding the tumor 
antigen MZ2-E was cloned (van der Bruggen, Traversari et al. 1991; Traversari, van der 
Bruggen et al. 1992). The gene was termed Mage1 (then renamed MageA1) and closely 
related genes Mage2 (MageA2) and Mage3 (MageA3) were subsequently identified in the 
same cell line (Gaugler, Van den Eynde et al. 1994; Chomez, De Backer et al. 2001). 
Expression of MageA1 was detected in melanomas, some breast carcinomas and other tumor 
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types, but not in any normal tissues except testis (Chomez, De Backer et al. 2001). In the 
following years, 12 new closely related MAGE-A genes were identified and showed to be 
clustered at the Xq28 (De Plaen, Arden et al. 1994; Chen, Scanlan et al. 1997; Chomez, De 
Backer et al. 2001). A search for the gene responsible for the sex-reversal phenotype revealed 
a second cluster of MAGE genes, which encoded the MAGE-B genes and was located at 
Xp21.3 (Muscatelli, Walker et al. 1995). Subsequently, a third cluster, encoding the MAGE-C 
genes was identified at Xq26-27 (Chen, Gure et al. 1998; Lucas, De Smet et al. 1998; Gure, 
Stockert et al. 2000). MAGE-A, MAGE-B and MAGE-C genes form the MAGE-I subfamily 
of tumor-specific MAGE genes. 
 
 
Table A: The MAGE family genes
T: expressed in tumor or germinal cells. P: pseudogene. N: expressed in
normal cells. -: unknown.
Type Subtype Genename
Length of 
amino acids
Expression
status
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b) Structure, classification and organization of MAGE genes 
 
The principal feature of MAGE proteins, is a large central region termed MAGE homology 
domain (MHD). The MHD is a sequence of 165-171 amino acids, generally found near the C-
terminus of the protein. This domain corresponds to a region of high homology and it is 
shared by all the members of the MAGE family (Fig. B). The MHD is present in proteins of 
many multicellular organisms, including Drosophila, Aspergillus and Arabidopsis thaliana 
but is apparently lacking in Caenorhabditis elegans and in unicellular organism such as 
protozoa (Chomez, De Backer et al. 2001; Barker and Salehi 2002). However, it has recently 
been reported that the yeast protein Nse3 shows significant level of homology with human 
MAGE proteins (Sergeant, Taylor et al. 2005). In humans the MHDs can be subdivided into 
five distinct regions that represent distinct areas of conservation (Fig. C). Subdomains 1, 3, 
and 5 are very similar, while the linker sequences are the less conserved portions of the MHD 
(Fig. C). Structural predictions based on the aligned MHD sequences suggest that the MHD 
contains at least four potential α–helical domains and five regions of β-sheet structure, but the 
true structure of this domains remains unresolved (Fig. C) (Barker and Salehi 2002). Despite 
its intra- and inter-species conservation, the MHD shows no significant homology to other 
proteins that would provide clues to its cellular function. 
 
Mage Homology Domain
Fig. B: Schematic representation of MAGE proteins. The percentage of identical amino 
acids between the MAGE conserved domains are indicated. Different fillings of the N-
and C- terminal regions of the proteins represent sequences that share no homology.  
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Fig. C: Schematic representation of the MHD structure. Black boxes represent 
highly conserved regions, while lines represent less conserved regione.
Cylinders and arrows represent predicted α-helices and β-sheets, respectively.  
 
 
Based on expression profiles, MAGE genes were classified as belonging to either subgroup I 
(MAGE-I genes) or II (MAGE-II genes) (Barker and Salehi 2002). MAGE-I genes include 
three subfamilies that cluster at the X-chromosome, MAGE-A at Xq28, MAGE-B at Xp21 
and MAGE-C at Xp26-27 (Fig. D). The expression of these genes is restricted to some 
malignant tumors, testis and placenta, but is not found in other normal tissues (Chomez, De 
Backer et al. 2001). For this reason, these genes belong to the expanding group of genes 
termed cancer/testis antigens (CTA). Most of MAGE-I proteins consist of little more than a 
single highly conserved MHD flanked by a small amount of poorly conserved N- and C-
terminal sequence (Barker and Salehi 2002). MAGE-II genes include the subfamilies MAGE-
D, -E, -F, -G, -H, -I, -J, -K and L2, that localize in chromosome 3, 15 and X (Fig. D). These 
genes are expressed in various normal adult human tissues. Some MAGE-II proteins (Necdin, 
MAGE-F and -G) show a structure similar to that of MAGE-A and –B, however others 
(MAGE-D, -E and –L) are larger proteins with extended N- or C-termini and in some cases 
contain a second, less conserved MHD (MHD2) (Fig. E). The ORFs of several MAGE-II 
genes are encoded by multiple exons and some give rise to alternative spliced mRNAs 
(Barker and Salehi 2002).  
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Fig. D: Chromosomal locations of the human MAGE subfamilies.  
 
 
 
Fig. E: Domain structures of selected MAGE family members, with the MHD indicated in yellow and MHD2 in 
green.  Alternatively spliced isoforms of MageD3 and D4 are indicated in boxes. The jagged lines in the MHDs
in MageE1and H1 indicate the presence of truncated MHDs.  
 
 
Phylogenetic analysis of the MHD sequences showed that type I and type II genes define 
distinct branches within the MAGE family (Fig. F) (Barker and Salehi 2002).  
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Fig. F: Phylogenetic tree of aligned MHDs.  
 
 
Structural analysis of MAGE genes suggest that they derived from an ancestral gene, 
probably belonging to MAGE-D, due to the high level of complexity of this subfamily, by 
processes of retroposition and further duplication, events that probably occurred more 
recently, thus indicating an unusually rapid evolution of this gene family (Chomez, De Backer 
et al. 2001).  
 
c) Regulation of MAGE genes expression 
 
MAGE-I genes are ideal targets for cancer vaccines because of their expression in a wide 
range of human tumors. Indeed, recent clinical studies showed promising results in anticancer 
immunotherapy against MAGE-I antigens (Marchand, van Baren et al. 1999; Hersey, 
Halliday et al. 2008; Zhang, Zhang et al. 2008). Nevertheless, heterogeneous intratumor 
expression of MAGE-I genes may hamper the effectiveness of these therapies and this has 
increased the interest in the analysis of the regulation of the expression of these genes.  
The expression of the various MAGE-I genes varies greatly among tumor types and they are 
frequently co-expressed in the same tumor, suggesting a possible cooperative effect in 
favoring the malignant phenotype through different functions that may act in synergy. These 
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observations are also consistent with MAGE-I expression being the result of the activation of 
a coordinated gene-expression program, rather than being independent events. 
A critical element in the induction of CTA genes expression (including MAGE-I) appears to 
be promoter demethylation. Methylation of CpG islands within gene promoters is responsible 
for gene silencing, due to both its effect on chromatin structure and to transcription factor 
binding (Baylin and Herman 2000). Alterations in DNA methylation and chromatin re-
structuring, occur during two phases in the human life cycle: gametogenesis and early 
embryogenesis (Kimmins and Sassone-Corsi 2005). So far, all CTA genes studied have 
methylated CpG islands in normal somatic tissues and are activated by demethylation during 
spermatogenesis (Weber, Salgaller et al. 1994; De Smet, De Backer et al. 1996; De Smet, 
Lurquin et al. 1999). Global DNA hypomethylation and gene-specific hypomethylation are 
processes which often accompany tumorigenesis and global hypomethylation in tumors has 
been correlated with CTA gene expression.  
Recent studies have demonstrated the relevance of DNA methylation on the regulation of 
MAGE-I expression. Demethylating agents such as 5-Aza-2’-Deoxycytidine (5-aza-CdR), 
and more recently valproate, have shown to induce the expression of MageA1 and MageB2, 
respectively, in tumor cells that do not express these genes and in several normal cell lines 
(Weber, Salgaller et al. 1994; De Smet, De Backer et al. 1996; Karpf, Lasek et al. 2004; 
Milutinovic, D'Alessio et al. 2007). Further studies revealed that cells that do not express 
MageA1 nevertheless contain transcription factors capable of inducing significant MageA1 
promoter activity, Ets transcription factor being responsible for its expression (De Smet, De 
Backer et al. 1996). This implied that lack of MageA1 transcription in somatic cells requires a 
local repression mechanism to prevent activation by these ubiquitous transcriptions factors. A 
CpG-rich promoter was defined in the promoter of MageA1, which unlike classical CpG-rich 
promoters, is methylated in all normal somatic tissues (De Smet, Lurquin et al. 1999). 
Moreover, although MZ2-MEL melanoma cells contain an active unmethylated MageA1 
gene, they lack the ability to induce demethylation of newly integrated MageA1 transgenes 
previously methylated in vitro before transfection. In the same cells unmethylated MageA1 
transgenes were protected against remethylation, and this appeared to depend on the level of 
transcriptional activity. Therefore, it was proposed that hypomethylation of MageA1 in 
tumors relies on a past demethylation event and on the presence of appropriate transcription 
factors that maintain the promoter unmethylated (De Smet, Loriot et al. 2004). Moreover, by 
using this cellular system it was shown that transient down-regulation of the DNA 
methyltransferase DNMT1 leads to the activation and stable hypomethylation of MageA1 
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(Loriot, De Plaen et al. 2006). Similar results were obtained by double knockout of DNMT1 
and DNMT3b (James, Link et al. 2006) or in knockout mice for the Histone H3 Lys 9 (H3-
K9) methyltrasferase, GLP/Eu-HMTase1 (Tachibana, Ueda et al. 2005). Altogether these data 
evidence the importance of epigenetic regulatory mechanisms for the control of MAGE-I 
expression. 
In addition, other reports have suggested that chromatin remodeling mechanisms, like histone 
acetylation, could contribute to MAGE-A expression. It was demonstrated that treatment with 
the histone deacetylase (HDAC) inhibitor Trichostatin A up-regulates the expression of 
MAGE-A genes as induced by demethylating agents (Wischnewski, Pantel et al. 2006). 
BORIS (Brother of the regulator of imprinted sites) is a recently identified CTA (Loukinov, 
Pugacheva et al. 2002), which encodes a paralogous of CTCF (CCCTC-binding factor), an 
ubiquitously expressed nuclear factor involved in genetic regulatory processes, such as 
context-dependent transcription silencing or activation, and organization of epigenetically 
controlled chromatin insulators that regulates imprinted genes in somatic cells. Like CTCF, 
BORIS contains an 11-zinc finger domain that mediate interaction with specific cis-regulatory 
sequences. These proteins are expressed in a mutually exclusive fashion during the 
development of male germ cells. In particular, demethylation events are associated with the 
expression of BORIS and with CTFC silencing, suggesting a complementary function of the 
two proteins during development and differentiation of the male germ line. BORIS is 
expressed also in many tumor types, and maps in a region (20q13) highly amplified in some 
cancer cells, its expression favors proliferation and neoplastic transformation (Klenova, 
Morse et al. 2002). Recent studies have demonstrated that BORIS is implicated in the 
expression of some CTAs, including MAGE-I genes, like MageA1, A2, B1 and B4 (Vatolin, 
Abdullaev et al. 2005). Conditional expression of BORIS in normal cells leads to induction of 
MageA1 through binding and consequent demethylation of MageA1 promoter. Moreover, 
BORIS seems to be important for the expression of CTAs after addition of demethylating 
agents. Nevertheless, a more recent work revealed that many melanoma cells express 
MageA1 and other CTAs in the absence of BORIS activation, suggesting that BORIS is 
neither necessary nor sufficient for the activation of other CTAs (Kholmanskikh, Loriot et al. 
2008). 
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d) Functions of MAGE genes 
 
Because many MAGE genes are highly homologous and are co-regulated and often co-
expressed during gametogenesis and tumorigenesis, it has been suggested that many of them 
could have redundant functions. Moreover, since the discovery of MAGE proteins, most of 
the studies were focused on targeting these proteins for antitumor immunotherapies; and 
analysis of their expression in different tumors being mostly used as a prognostic tool. For 
these reasons their biological functions have remained poorly characterized. A central 
question is whether MAGE expression contributes directly to tumorigenesis or is a functional 
irrelevant by-product of the process of cellular transformation, possibly associated with 
global-chromatin changes. Clues have emerged, however, to indicate that expression of 
MAGE genes could have a role in human tumorigenesis (Simpson, Caballero et al. 2005). In 
fact MAGE-I genes expression could be detected in early phases of lung and breast 
carcinogenesis and, in addition, it has been demonstrated that cells expressing MAGE-I 
members acquire chemoresistance (Jang, Soria et al. 2001; Otte, Zafrakas et al. 2001; Seth, 
Krop et al. 2002).  
Within MAGE-I subfamily, MAGE-A proteins are the best characterized. By yeast two 
hybrid assays it was identified the transcriptional regulator SKI-interacting protein (SKIP) as 
a binding partner for MageA1. Binding of MageA1 to SKIP depends on the extreme carboxyl 
terminus of the MAGE protein. SKIP connects DNA-binding proteins to other proteins that 
either activate or repress transcription, and participates in a wide range of signaling pathways, 
including those involving vitamin D, retinoic acid, estrogens, glucocorticoids, NOTCH1 and 
transforming growth factor-β. In the NOTCH1 pathway, MageA1 was found to disrupt the 
SKIP-mediated NOTCH1 signal transduction by binding to SKIP and recruiting histone 
deacetylase. Therefore, at least in this signaling pathway MageA1 can act as transcriptional 
repressor (Laduron, Deplus et al. 2004). The function of MageA1 in the germ line has not 
been elucidated. It is likely that MageA1 represses the expression of genes required for 
differentiation, as it is expressed in spermatogonia but not during later developmental stages.  
Recent data indicate that expression of certain MAGE-A genes in cancer cells contributes 
directly to the malignant phenotype and response to therapy. In particular, the relationship 
between sensitivity to tumor necrosis factor (TNF) and MageA1, MageA2 or MageA3 
expression was examined in a range of human cell lines, where it was found that cell lines 
expressing at least one of the three MAGE genes were more resistant to TNF-mediated 
cytotoxicity (Park, Kong et al. 2002). It has also been shown that MageA2 or MageA6 genes 
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lead to the acquisition of resistance to chemotherapeutic drugs such as paclitaxel and 
doxorubicin in human cell lines (Bertram, Palfner et al. 1998; Duan, Duan et al. 2003; Glynn, 
Gammell et al. 2004; Suzuki, Yoshida et al. 2007). 
MageA4 was identified as a partner for the oncoprotein gankyrin. Both MageA4 and gankyrin 
are frequently overexpressed in hepatocellular carcinomas (Fu, Wang et al. 2002; Nagao, 
Higashitsuji et al. 2003). Gankyrin destabilizes the retinoblastoma tumor suppressor, 
contributing to entry into the cell cycle and escape from cell-cycle arrest and/or apoptosis; in 
addition it binds the cyclin-dependent kinase 4 (Cdk4) inhibiting subsequent interaction with 
p16INK4A and p18INK4C (Li and Tsai 2002). Finally, gankyrin binds Mdm2 to facilitate the 
binding and consequent ubiquitination and degradation of p53 (Higashitsuji, Higashitsuji et al. 
2005). MageA4 suppresses these activities through its binding to gankyrin, consequently 
inhibiting both anchorage-independent growth in vitro and tumor formation in athymic mice 
of gankyrin-overexpressing cells (Higashitsuji, Itoh et al. 2000). This repressive effect of 
MageA4 occurs through the action of a peptide that is naturally cleaved from the carboxyl 
terminus of MageA4, which induces p53-independent apoptosis (Sakurai, Itoh et al. 2004). 
MageA4 negatively regulates the expression of p21Cip1 through the binding of the 
transcription factor Miz-1, found to be an interactor of MageA4 by yeast two hybrid analysis. 
More recently it has been demonstrated, that in non-small cell lung carcinomas MageA4 can 
induce apoptosis and that treatment of these tumors with the chemotherapeutic agent 
etoposide seems to increase the apoptotic effect (Peikert, Specks et al. 2006). 
MageA11 was found to have a role in the regulation of androgen-receptor function by 
modulating its internal domain interactions (Bai, He et al. 2005). MageA11 stabilizes ligand-
free androgen receptor in the cytoplasm, leading to its accumulation. In the presence of 
agonist, the exposure of the amino-terminal ligand-binding domain of the receptor increases 
the recruitment of SRC/p160 co-activators, consequently amplifying the transcriptional 
activity of the pathway. Binding between MageA11 and the androgen-receptor is regulated by 
the epidermal growth factor (EGF)-dependent phosphorylation and ubiquitination of 
MageA11 (Bai and Wilson 2008). 
Recent studies have demonstrated that the small interfering RNA (siRNA) mediated 
suppression of MAGE-A, -B and –C gene expression slows proliferation and induces caspase 
independent apoptosis in human and murine mast cell lines, and suppresses growth of 
malignant cells in an in vivo murine model of mastocytosis (Yang, O'Herrin et al. 2007).  
Altogether, these studies formly point to the functional roles of MAGE-I proteins expression 
in the regulation of proliferation/survival of tumor cells. 
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Among MAGE-II proteins, Necdin is the better characterized one. Necdin is a neural 
differentiation-associated gene product isolated from murine embrional carcinoma P19 cells 
(Maruyama, Usami et al. 1991). The Necdin gene is expressed in most of the postmitotic 
neurons through the central nervous system and peripheral nervous system (Maruyama, 
Usami et al. 1991; Aizawa, Maruyama et al. 1992; Niinobe, Koyama et al. 2000). Necdin 
strongly suppresses cell proliferation, promotes neuronal differentiation, and inhibits death of 
several cell lines and primary neurons (Hayashi, Matsuyama et al. 1995; Taniura, Taniguchi 
et al. 1998; Kobayashi, Taniura et al. 2002; Takazaki, Nishimura et al. 2002; Kuwako, 
Hosokawa et al. 2005). Necdin binds to many regulatory proteins such as the transcription 
factors E2F1, E2F4, and p53 leading to the repression of their transcriptional activity and 
consequently inhibiting cell growth and apoptosis (Taniura, Taniguchi et al. 1998; Taniura, 
Matsumoto et al. 1999; Kuwako, Taniura et al. 2004; Kurita, Kuwajima et al. 2006; Hasegawa 
and Yoshikawa 2008). Necdin binds also to the neurotrophin receptors p75, TrkA 
(Tcherpakov, Bronfman et al. 2002; Kuwako, Taniura et al. 2004; Kuwako, Hosokawa et al. 
2005) and to the Dlx (distal-less homeobox) homeodomain proteins through its binding to 
MageD1 (another MAGE-II family member), promoting differentiation of GABAergic 
neurons (Kuwajima, Nishimura et al. 2006). Since all these interactors are involved in cell 
cycle regulation, differentiation, and apoptosis, necdin may play an integral role in mitotic 
arrest, differentiation, and survival of postmitotic neurons (Yoshikawa 2000; Andrieu, 
Meziane et al. 2006). More recently it has been reported that Necdin expressed in skeletal 
muscle cells mediates muscle regeneration by promoting myoblast survival and differentiation 
(Deponti, Francois et al. 2007; Bush and Wevrick 2008). The human Necdin gene is located 
in chromosome 15q11-q12 (Nakada, Taniura et al. 1998), a region deleted in the genomic 
imprinting-associated neurobehavioral disorder Prader-Willi syndrome (PWS). The Necdin 
gene is maternally imprinted and expressed only from the paternal allele in human and mouse 
(Jay, Rougeulle et al. 1997; MacDonald and Wevrick 1997). Furthermore, Necdin-deficient 
mice display several phenotypes such as postnatal lethality, impaired neuronal development, 
and abnormal behaviors, which are consistent with some of the PWS symptoms (Gerard, 
Hernandez et al. 1999; Muscatelli, Abrous et al. 2000; Ren, Lee et al. 2003; Kuwako, 
Hosokawa et al. 2005; Zanella, Watrin et al. 2008). These findings suggest that deletion of the 
paternal Necdin allele leads to the abnormal development of specific neurons in PWS. 
MageL2 is also an imprinted gene that, similarly to Necdin, maps to the same chromosomal 
region associated with PWS. It is expressed predominantly in the developing central nervous 
system, particularly within hypothalamus, cerebral cortex, and spinal cord (Boccaccio, Glatt-
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Deeley et al. 1999; Lee, Kozlov et al. 2000). Highest MageL2 expression levels are observed 
during neurogenesis. The tissue specific and developmental expression pattern of MageL2 is 
consistent with a role in the PWS (Kozlov, Bogenpohl et al. 2007).  
MageD1, also named NRAGE or Dlxin, plays important roles in regulation of apoptosis and 
transcription. NRAGE interacts with p75 neurotrophin receptor (p75NTR), a TNF receptor 
family member responsible for binding the tyrosine kinase receptor (Trk) and forming a 
complex that facilitates binding of neurotrophin, which in turn activates the Trk receptor.  
p75NTR  is also capable of mediating cell death (Barker 1998; Barrett 2000; Kaplan and Miller 
2000). NRAGE- p75NTR binding occurs through the intracellular segment of p75NTR located 
near the plasma membrane. Overexpression of NRAGE inhibits the interaction between 
p75NTR and the Trk receptor and induces cell apoptosis (Salehi, Roux et al. 2000). Another 
NRAGE-binding protein, XIAP, a member of the inhibitors of apoptosis family (IAP), can 
inhibit apoptosis by binding to activated caspases. The NRAGE-XIAP complex facilitates the 
degradation of XIAP, suggesting that NRAGE accelerates cell death by degrading XIAP and 
activating caspases (Jordan, Dinev et al. 2001). Other works suggested that NRAGE can 
induce cell death by other mechanisms. NRAGE interacts and inhibits Che-1, (also known as 
apoptosis-antagonizing transcription factor (AATF), a protein involved in cell cycle control 
and gene transcription), by sequestering Che-1 to the cytoplasmic compartment and targeting 
it for proteasome-dependent degradation (Di Certo, Corbi et al. 2007). 
MageD1 interacts also with homeodomain proteins Msx2, Dlx7 and Dlx5, that participate in 
the development of the craniofacial, limbic and nervous systems (Bendall and Abate-Shen 
2000). Msx genes are expressed in dividing or in apoptotic cells, and they behave as 
transcriptional repressors controlling cell cycle. Dlx genes are expressed in developing cells 
and behave as transcriptional activators. The effect of MageD1 binding to these genes remains 
unknown, but it was demonstrated that MageD1 is required for Dlx5 activity (Masuda, Sasaki 
et al. 2001). The activity of MageD1 on Msx2 is also regulated by Ror2, a membrane tyrosine 
kinase receptor that control morphogenetic development (Schlessinger 2000). Ror2 binds the 
c-terminus of MageD1, sequestering it to the plasmatic membrane and inhibiting its 
interaction with nuclear Msx2 (Matsuda, Suzuki et al. 2003). In addition, MageD1 interacts 
with Praja1, an ubiquitin ligase protein that regulates the transcriptional function of Dlx5 by 
inducing MageD1 degradation (Sasaki, Masuda et al. 2002). 
It was also reported that MageD1 binds BRCA-2, an important factor in the double strand 
break repair process and many other cellular functions such as inhibition of cell proliferation. 
Mutations of BRCA-2 at the germinal level favor the predisposition to breast and ovarian 
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carcinomas. Binding between MageD1 and BRCA-2, induces MageD1 stabilization and 
seems to be required for the p53-dependent anti-proliferative function of BRCA-2 (Tian, Rai 
et al. 2005). 
Moreover, more recently it was suggested that MageD1 can suppress the motility and 
adhesion response of tumor cells by interfering with actin cytoskeleton reorganization and 
hypoxia inducible factor 1-dependent gene expression (Shen, Xue et al. 2007). 
 
 
The p53 tumor suppressor protein 
 
The tumor suppressor p53 was first identified in 1979 (DeLeo, Jay et al. 1979; Lane and 
Crawford 1979; Linzer and Levine 1979), and since then it becomes one of the most studied 
protein in human diseases, primarily because the majority of human tumors have defects in 
the p53 pathway. Through nearly 30 years of intensive studies, extensive knowledge has been 
achieved on the p53 pathway and a great extent of complexity has been unveiled.  
The importance of p53 in cancer development is illustrated by the fact that cancer cells can 
escape the tumour suppression function of p53 through missense mutations of the p53 gene. 
Actually, 50% of human cancers carry mutations in the p53 gene (Olivier, Hussain et al. 
2004). In addition, other components of the p53 pathway are frequently altered in tumours 
bearing wild type p53. Is thus possible to suggest that the p53 pathway is compromised to 
some degree in all human cancers. 
p53 has a short-half life and is normally maintained at low levels in unstressed cells by 
continuous ubiquitylation and subsequent degradation by the 26S proteasome (Haupt, Maya et 
al. 1997; Kubbutat, Jones et al. 1997). However, in response to a large number of stress 
signals, including DNA damage, oncogene activation, viral infection, telomere erosion, 
hypoxia, temperature change, nucleolar disruption and nucleotide depletion, p53 is rapidly 
stabilized and accumulates in the nucleus, where it forms a homotetrameric complex 
(Friedman, Chen et al. 1993). Only tetrameric p53 seems to be fully active as transcriptional 
activator or repressor of distinct target genes that contain p53 sequence-specific binding sites 
(Davison, Yin et al. 1998). Furthermore, p53 interacts with more than 100 cellular proteins 
and influences the cellular response to stress signals through transcription-dependent and –
independent pathways (Fuster, Sanz-Gonzalez et al. 2007). Thus, p53 functions as a key 
integrator that translates diverse stress signals into different cellular outcomes, ranging from 
cell-cycle arrest, DNA repair/genome stability, apoptosis, autophagy, cell migration and 
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senescence, to differentiation, embryo implantation, regulation of metabolism, and 
angiogenesis (Murray-Zmijewski, Slee et al. 2008). 
The activity of p53 is tightly regulated, and depending on the stimulus and the cellular 
environment, the protein undergoes a series of post-translational modifications, that affect its 
stability, sub-cellular localization and its ability to interact with different co-factors and to 
bind to its target promoters. The most commonly reported post-translational modifications of 
p53 include phosphorylation of serines and/or threonines and acetylation, ubiquitylation, 
sumoylation, neddylation and methylation (Bode and Dong 2004; Murray-Zmijewski, Slee et 
al. 2008).  
 
a) Structure of the p53 protein 
 
The p53 protein consists of 393 amino acids and is commonly divided into three functional 
domains, the N-terminal, the central core and the C-terminal domains (Fig. G). 
 
 
Fig. G: Schematic representation of the p53 functional domains  
 
  
The acidic amino-terminal domain, or the transactivation domain (TA, amino acids 1-62), is 
required for transcriptional activation (Fields and Jang 1990). This portion is sufficient to 
activate transcription by interaction with components of the basal transcriptional machinery 
like the TATA-binding protein (TBP) and TBP associated proteins (TAFs) as well as with 
p300/CBP (Liu, Miller et al. 1993). The transcriptional activation domain is finely regulated 
both by post-translational modifications and by interaction with protein partners such as 
p300/CBP, Mdm2 and Pin1. Mdm2, the most critical negative regulator of p53, interacts with 
residues 17–27 and mediates the ubiquitination of p53 C-terminal lysine residues. Moreover 
Mdm2, together with MdmX, prevents the binding of transcriptional co-activators such as 
p300, interfering with the transactivation function of p53.  
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Adjacent to the transactivation domain there is a proline-rich domain (PRD, amino acids 63-
97) containing five repeats of the amino acid motif PXXP (where P designates proline and X 
any amino acid) in humans while only two in mice (Walker and Levine 1996). This region 
was thought to be significant for p53 regulation since PXXP motifs create binding sites for 
Src homology 3 (SH3) domain-containing proteins and can modulate signal transduction 
(Kay, Williamson et al. 2000). Indeed, the p53 PXXP motifs may contribute to interactions 
with the transcription co-activator p300 (Dornan, Shimizu et al. 2003) thus influencing p53 
acetylation. Furthermore, the prolyl isomerase Pin1 binds to Thr81-Pro82 site upon Thr81 
phosphorylation and induces a conformational change on Pro82. This may reduce Mdm2 
binding thus influencing p53 stability (Wulf, Liou et al. 2002; Zacchi, Gostissa et al. 2002), 
consistently with other evidence indicating that the PRD modulates Mdm2 binding (Berger, 
Vogt Sionov et al. 2001; Dumaz, Milne et al. 2001). Furthermore, the functional importance 
of the PRD is suggested by studies showing that this domain is dispensable for cell cycle 
arrest but is essential for apoptosis (Sakamuro, Sabbatini et al. 1997; Venot, Maratrat et al. 
1998) being required both for transcriptional activation of pro-apoptotic genes (Bergamaschi, 
Samuels et al. 2006) and for direct apoptotic function of p53 at mitochondria (Chipuk, 
Kuwana et al. 2004). Yet, a recent study conducted in mice indicated that, although the PRD 
may play some role in the regulation of p53, as mice p53∆P (that bear p53 lacking the PRD) 
display increased Mdm2-mediated degradation and decreased transactivation capacity 
(Toledo, Lee et al. 2007), the PXXP motifs are not essential for p53 tumor suppressor 
functions, as their depletion does not significantly affect p53 accumulation and  
transactivation, and exhibits only little effect on cell cycle control or apoptosis. 
The core domain of p53 (amino acids 98-292) contains the sequence-specific DNA binding 
domain (DBD) required for p53 to function as a transcriptional activator (el-Deiry, Kern et al. 
1992). The canonical p53-responsive element contains two decamers or half sites, 
PuPuPuC(A/T)(A/T)GPyPyPy, which are separated by a spacer of 0–13 base pairs. Several 
studies indicate that a p53 monomer binds the pentameric sequence and that a tetramer binds 
the full consensus site (Cho, Gorina et al. 1994; Ma, Pan et al. 2005). The crystal structure of 
the p53-DBD bound to DNA has revealed that the conserved regions are crucial for the p53–
DNA interaction (Cho, Gorina et al. 1994). The larger part of the DBD forms an antiparallel 
β-sandwich. This β-sandwich serves as a scaffold that supports the structures important for the 
interaction with DNA, specifically two large loops and a loop-sheet-helix motif. Most of the 
interactions between p53 and its target proteins take place in the DBD of p53. The importance 
of sequence-specific DNA binding for p53 to function as a tumor suppressor is highlighted by 
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the fact that 97% of tumor-associated mutations cluster in this domain (Sigal and Rotter 
2000). The mutations situated in the DBD can disrupt specific DNA binding by several 
possible ways. Mutations at some positions (e.g. Arg273His) lose direct contacts with DNA 
and are therefore named “contact mutants” (Cho, Gorina et al. 1994; Bullock, Henckel et al. 
1997). Some other mutants, defined “conformational mutants” (e.g. Arg175His, Gly245Ser, 
Arg249Ser, Arg282Trp) show reduced binding due to destabilization of the tertiary structure 
of p53 DBD (Wong, DeDecker et al. 1999; Bullock, Henckel et al. 2000). Mutation at 
position 248 (Arg248Trp), in addition to breaking DNA-protein contacts, also introduces 
extensive structural changes into the DBD (Wong, DeDecker et al. 1999).   
The tetramerization domain (amino acids 300-355) of p53, is linked to the DBD by a 
flexible linker. This region consists of a β-sheet structure that determines the dimeric 
association and an α-helical structure that mediates the successive association between two 
dimmers (Lee, Harvey et al. 1994; Jeffrey, Gorina et al. 1995). Tetramerization is required for 
efficient transactivation by p53 (Pietenpol, Tokino et al. 1994). This domain contains also the 
nuclear localization signal (NLS) (amino acids 316-325) and the nuclear export signal (NES) 
(amino acids 340-351). 
The last 30 amino acids of p53 constitute a basic C-terminal domain (CT, amino acids 363-
393) that has been regarded as a regulatory domain due to its ability to influence p53 
activity. A great number of post-translational modifications occur in this domain upon stress-
signalling. Nearly every residue within this domain is in fact subjected to at least one post-
translational modification. This domain does not form a regular secondary structure and is 
able to interact directly with DNA and RNA (Lee, Elenbaas et al. 1995; Ayed, Mulder et al. 
2001). In particular CT is able to bind ssDNA ends, insertion/deletion mismatches, 
recombination intermediates and γ-irradiated DNA in vitro thus implying its ability to 
recognize damaged DNA and DNA repair intermediates in vivo (Bakalkin, Selivanova et al. 
1995; Lee, Elenbaas et al. 1995; Zotchev, Protopopova et al. 2000). Moreover some recent 
works demonstrated that the CT is important for binding to non-linear DNAs (McKinney and 
Prives 2002; Fojta, Pivonkova et al. 2004; Palecek, Brazda et al. 2004) and is involved in the 
ability of p53 to diffuse linearly on DNA (McKinney, Mattia et al. 2004). These studies also 
revealed that the CT is required for efficient promoter activation by p53. 
 
The family of p53 related transcription factors includes its homologues p63 and p73 (Kaghad, 
Bonnet et al. 1997; Yang, Kaghad et al. 1998). p53 family members have high structural 
similarity (Fig. H). They all contain the central DNA binding domain (DBD), the N-terminal 
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transactivation domain (TA) and the oligomerization domain (OD). p63 and p73 are 
transcribed from two major promoters thus can be expressed with (TA forms) or without (∆N 
forms) the amino terminal TA domain (Stiewe, Zimmermann et al. 2002). Moreover, p63 and 
p73 splicing variants, designated by greek letters, differ in the regions at the carboxy terminal 
end. Here also resides the most obvious structural difference between p53 and its siblings 
consisting in the fact that the α-forms of p63 and p73 contain a sterile α motif (SAM) that is 
absent in p53 (Kim and Bowie 2003). The homology shown by p53, p63 and p73 had first 
suggested that the products of this gene family share similar or even redundant functions. 
However, difference in regulation and activity among the p53 members emerged quite 
rapidly. Many reports highlighted that the three members of p53 family might be critical 
regulators of different processes. In particular, p53 is mainly involved in DNA-damage 
response while p73 and p63 play key roles in development. This is strikingly highlighted by 
the phenotypes of mice with targeted deletions for each of the three family members. While 
p53-null mice are tumor-prone, underlining the key function of p53 in tumor suppression, 
they lack a clear developmental phenotype that is instead evident upon disruption of p63 and 
p73 (Yang, Schweitzer et al. 1999; Yang, Walker et al. 2000; Pellegrini, Dellambra et al. 
2001; Brunner, Hamel et al. 2002). Interestingly, phylogenetic analysis demonstrated that the 
primordial ancestor of all three genes is actually much more related to p63 and p73, while p53 
appears as the most recently evolved member of its family (Yang, Kaghad et al. 2002). It 
might be hypothesized that p53 lost some of its ancestral functions that are instead carried out 
by its homologues, yet it has gained the ability to protect cells from tumorigenesis. This seems 
also to be confirmed by the evidence that p53 is mutated in almost 50% of all human 
malignancies, while mutations in the p63 and p73 genes are rare (Nomoto, Haruki et al. 1998; 
Irwin and Kaelin 2001). However, there are reports showing that also p63 and p73 have tumor 
suppressive activities in human tumors. On the one hand they contribute to p53 tumor 
suppression, as it has been shown that mice heterozygous for mutations in both p53 and p63 
or p53 and p73, lead to a more aggressive tumor phenotype (Flores, Sengupta et al. 2005) and 
that p53 requires at least one of its homologues to function properly as an inducer of pro-
apoptotic genes upon DNA damage (Flores, Tsai et al. 2002). On the other hand they might 
have a specific role in tumor suppression as their loss or down-regulation leads to 
tumorigenesis at specific tissues (Ahomadegbe, Tourpin et al. 2000; Park, Lee et al. 2000; 
Puig, Capodieci et al. 2003; Park, Kim et al. 2004) with a tumor spectrum that differs from 
that of p53 and that reflects their pattern of expression. 
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Fig. H: Gene architecture of the p53 family. The p53 family includes the
three genes p53, p63, and p73. They have a modular structure consisting
of the TA, the DBD, and the oligomerization domain. All genes are 
expressed as two major types: full-length proteins containing the TA 
domain and DN proteins missing the TA domain. The products of p73 
and p63 are more complex than p53 and contain a COOH-terminal SAM 
domain and a transactivation inhibitory domain in their a isoforms. p63 
and p73 also contain two promoters. The P1 promoter in the 5V
untranslated region produces TA proteins that are transcriptionally active,
whereas the P2 promoter produces DN proteins with dominant-negative
functions toward themselves and toward wild-type p53. In addition, 
extensive COOH-terminal splicing and, in TP73, additional NH2-terminal
splice variants of the P1 transcript further modulate the p53-like functions 
of the TA proteins.  
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b) p53 protein regulation 
 
When cells respond adequately to p53-activating signals, the consequent biological outcome 
may vary considerably. As it appears from a large number of studies, much of the choice does 
not depend on p53 itself. Rather it is the cellular context, as defined by the balance of 
intracellular and extracellular signalling events which dictates the direction undertaken by p53 
response. Multiple proteins contribute to the activation of p53 in response to diverse stress 
stimuli. These include proteins that modify p53 for both stabilization and transcriptional 
activation, that reverse these modifications, that enhance the translation of p53 mRNA or that 
alter its subcellular localization. 
 
b.1) Regulation of p53 stability 
 
In the absence of stress, p53 abundance is maintained at very low levels. Multiple lines of 
evidence indicate that MDM2 and MDMX play a major role in regulating p53 stability.  
MDM2 was first isolated from a mouse double minute chromosome that was present at a high 
copy number in a spontaneously transformed derivative of mouse 3T3 cells (Cahilly-Snyder, 
Yang-Feng et al. 1987). Its role as an oncogene was assessed after the observation that its 
over-expression lead to immortalization of rodent primary fibroblasts and induced a fully 
transformed phenotype in cultured cells. Early studies ascribed the transforming capabilities 
of MDM2 to its ability to form a complex with p53 (Momand, Zambetti et al. 1992) and to the 
observation that its overexpression leads to abrogation of both p53-mediated G1 phase cell 
cycle arrest and induction of apoptosis in cultured cells (Chen, Wu et al. 1996; Haupt, Barak 
et al. 1996). The MDMX oncogene was identified because of its ability to interact with p53 
(Shvarts, Steegenga et al. 1996) and later as a MDM2 partner (Tanimura, Ohtsuka et al. 
1999). Like MDM2, MDMX acts as an oncogene and both are found amplified in many 
cancers including soft tissue, breast, lung and small intestine cancer (Momand, Jung et al. 
1998; Danovi, Meulmeester et al. 2004). The two protein share a great structural similarity 
and are able to homo- and heterodimerize through their RING-finger domain (Tanimura, 
Ohtsuka et al. 1999). Importantly, the highest similarity among the two proteins resides in the 
region encompassing the p53 binding domain where the amino acid residues necessary for the 
interaction with p53 are strictly conserved (Freedman, Epstein et al. 1997). Conversely, the 
same amino acids on p53 are required for both the interaction with MDM2 and with MDMX 
(Bottger, Bottger et al. 1997). Yet, an important difference between MDM2 and MDMX is 
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that the RING domain of MDM2 is essential for its action as an E3-ubiquitin ligase, whereas 
MDMX apparently has no intrinsic ubiquitin-ligase activity. 
Genetic studies revealed that germ line inactivation of either MDM2 or MDMX leads to early 
embryonic lethal phenotypes that are completely overcome by concomitant inactivation of the 
p53 gene (Jones, Roe et al. 1995; Montes de Oca Luna, Wagner et al. 1995; Parant, Chavez-
Reyes et al. 2001; Finch, Donoviel et al. 2002; Migliorini, Lazzerini Denchi et al. 2002). 
These studies also indicated that MDM2 and MDMX are non-redundant p53 inhibitors, as 
normal levels of either regulator cannot compensate for the loss of the other.  These evidences 
clearly indicate that p53 is a key downstream target of MDM2/MDMX and that 
MDM2/MDMX are essential negative regulators of p53. 
MDM2 and MDMX mediate the inactivation of p53 through different molecular mechanisms. 
Both MDM2 and MDMX interfere with the transcriptional activity of p53. This was initially 
thought to occur by virtue of their binding to the N-terminal domain of p53, masking the 
transactivation domain of p53 (Oliner, Pietenpol et al. 1993), and disabling its interactions 
with the basal transcriptional machinery and essential co-factors (Chen, Lin et al. 1995). 
Indeed, MDM2/MDMX bind to the N-terminus of p53 within a domain that serves to recruit 
the histone acetyltransferases p300 and CBP  (Lambert, Kashanchi et al. 1998; Dumaz and 
Meek 1999) thus interfering with p53 acetylation by p300 (Kobet, Zeng et al. 2000; Sabbatini 
and McCormick 2002). MDM2 also associates with the histone deacetylase HDAC1, 
targeting it toward p53 deacetylation (Ito, Kawaguchi et al. 2002); MDM2 has also been 
shown to localize with p53 at its responsive elements on the p21 and MDM2 genes under 
normal growth conditions and to dissociate upon DNA damage (White, Talbott et al. 2006) 
thus suggesting that the recruitment of a MDM2-HDAC1 complex to chromatin might 
potentially promote histone deacetylation and transcriptional silencing. In addition, it has been 
reported that MDM2 is capable of binding directly to histones promoting their 
monoubiquitylation and leading to transcriptional repression (Minsky and Oren 2004). 
Moreover, MDM2 further inhibits p53 transcriptional functions by catalyzing the conjugation 
of NEDD8, a small ubiquitin-like protein, to p53 Lys-370, 372 and 373 (Xirodimas, Saville et 
al. 2004). 
The most important role played by MDM2 is however the regulation of p53 turn-over. MDM2 
is in fact an E3-ubiquitin ligase that upon binding to p53 can catalyze either mono- and poly-
ubiquitylation of p53, leading to nuclear export or proteasomal degradation, respectively (Li, 
Brooks et al. 2003). In contrast to MDM2, MDMX does not act as an E3 ubiquitin ligase and 
by itself cannot stimulate p53 ubiquitylation and proteasome-dependent degradation (Jackson 
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and Berberich 2000; Stad, Little et al. 2001). However, MDMX can stabilize MDM2 
preventing its auto-ubiquitylation (Sharp, Kratowicz et al. 1999; Stad, Little et al. 2001), 
while MDM2 mediates MDMX poly-ubiquitylation (Linares, Hengstermann et al. 2003; Pan 
and Chen 2003). 
It has been shown that MDM2 mediates both monoubiquitylation or polyubiquitylation of p53 
depending on its relative amount with respect to p53 (Li, Brooks et al. 2003): when MDM2 is 
abundant, it promotes effective p53 polyubiquitylation, leading to subsequent p53 degradation 
by the 26S proteasome. Several proteins have been demonstrated to assist the ubiquitylation 
of p53 by MDM2. Gankyrin increases the ubiquitin-ligase activity of MDM2 and p53 
degradation by favouring the association of the MDM2-p53 complex to the 26S proteasome 
(Higashitsuji, Higashitsuji et al. 2005). Moreover, transcription factor Yin Yang 1 (YY1), a 
protein that plays a key role in development, increases p53 degradation by stabilizing the 
complex p53-MDM2 (Sui, Affar el et al. 2004). Intriguingly, it has been shown that p300 
cooperates with MDM2 to promote p53 poly-ubiquitylation (Grossman 2001) by acting as an 
E4 ubiquitin ligase (Grossman, Deato et al. 2003). This reveals a complex interplay between 
the two proteins that needs further elucidation. 
Conversely, when MDM2 levels are scarce, p53 becomes monoubiquitylated and rather than 
being degraded, p53 is exported into the cytoplasm. Notably, MDM2 and p53 do not leave the 
nucleus together, it seems rather that mono-ubiquitylation of p53 by MDM2 leads to an 
unmasking of the NES within the C-terminus of p53 (Gu, Nie et al. 2001; Li, Brooks et al. 
2003). Movement of p53 into the cytoplasm has been thought for long time to have an 
inhibitory effect on p53 activity. Clearly, this translocation prevents p53 from transcriptional 
activation of its target genes, however it might be important for transcription-independent 
functions of p53 such as interactions with mitochondrial proteins in the apoptotic response 
(Mihara, Erster et al. 2003; Chipuk and Green 2004). 
On the other hand phosphorylation of MDM2 and MDMX enhances their degradation by 
auto-ubiquitylation and by reduction of their association with the de-ubiquitylating enzyme 
HAUSP, further releasing p53 from its negative regulation (Li, Chen et al. 2002; Li, Brooks et 
al. 2004; Brooks, Li et al. 2007).  
The p53-MDM2 interplay is tightly regulated in a negative feedback loop wherein p53 
stimulates MDM2 synthesis through transactivation of its promoter (which contains two 
adjacent p53 binding sites) while MDM2 inhibits p53 activity. Interestingly, MDMX is not a 
p53 transcriptional target and its abundance is mainly regulated through the interaction with 
HAUSP.  
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p53 stabilization and activation is furthermore regulated by other pathways that crosstalk with 
the p53-MDM2 axis. A feedback loop governing p53 activity involves the AKT kinase and 
the PIP-3 phosphatase PTEN. In detail, AKT phosphorylates MDM2 and induces its 
translocation into the nucleus, where it down-regulates p53 (Mayo, Dixon et al. 2002; Zhou, 
Gu et al. 2003). By inhibiting AKT and by blocking the nuclear entry of MDM2, PTEN 
sustains p53 activity (Mayo and Donner 2002). On the other hand, in damaged cells, p53 
activates the transcription of PTEN (Stambolic, MacPherson et al. 2001) thus facilitating 
formation of a cycle in which p53 induces PTEN and PTEN stabilizes p53.   
Upon increased oncogenic signalling, p53 activation and stability is regulated also by the 
tumor suppressor ARF. ARF increases p53 stability as it down-modulates MDM2 ubiquitin 
ligase activity both by sequestering it to the nucleolus (Honda and Yasuda 1999; Lowe 1999; 
Damalas, Kahan et al. 2001) and by interfering with its interaction with YY1 (Sui, Affar el et 
al. 2004). Notably p53 itself has been shown to down-regulate ARF expression (Robertson 
and Jones 1998). In this way increased levels of p53 act in a negative feedback, resulting in 
down-regulation of ARF transcription and concomitant decreases in ARF levels. This will 
then allow MDM2 to bind to p53 and reduce its stability by targeting it for degradation. 
Other proteins that act as E3 ubiquitin ligase have been shown to target p53 and promote its 
proteasome-mediated degradation. Pirh2, a RING-H2 domain-containing protein, interacts 
with p53 and promotes MDM2-independent p53 ubiquitylation and degradation (Leng, Lin et 
al. 2003). Similar to MDM2, Pirh2 is a p53 responsive gene and participates in a comparable 
auto regulatory negative feedback loop. Another E3 ligase, COP1, has also been described 
recently as a direct ubiquitin ligase for p53 (Dornan, Wertz et al. 2004). COP1 is also a p53-
inducible gene and can ubiquitinate and degrade p53.  
ARF-BP1/Mule/HectH9 was recently identified as a HECT domain E3 ligase that can 
ubiquitinate and degrade p53 (Chen, Kon et al. 2005). ARF interacts with ARF-
BP1/Mule/HectH9 and inhibits its activity thus leading to p53 stabilization. 
Another route to degradation for p53 is mediated by the ubiquitin ligase CHIP (chaperone-
associated ubiquitin ligase), that has been shown to poly-ubiquitinate p53 upon transient 
binding to HSP90 and HSP70. This mechanism might contribute to maintaining low levels of 
p53 under physiological conditions as CHIP depletion augment p53 basal levels (Esser, 
Scheffner et al. 2005). 
Recently, a family of ubiquitin ligases called caspase 8/10-associated RING proteins (CARPs) 
were described. CARPs target either unmodified p53 or p53 that has been phosphorylated on 
serine 20 for degradation, independently of MDM2 (Yang, Rozan et al. 2007). 
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b.2) Regulation of p53 by posttranslational modifications 
 
p53 undergoes a great variety of post-translational modifications that influence its stability 
and its transcriptional activity. These include phosphorylation of serines and threonines, 
acetylation, mono- and poly-ubiquitylation, sumoylation, neddylation and methylation of 
lysines. The actual pattern of post-translational modifications is complicated since the same 
residue might be modified in different ways by different enzymes. Notably nearly all of these 
modifications occur in the N-terminal or in the C-terminal domains.  
 
- Phosphorylation 
 
Many kinases, including ATM, ATR, Chk1, Chk2, casein kinase1 and 2 (CK1, CK2), c-JUN 
NH2-terminal kinase (JNK), Erk, p38, Aurora Kinase A, glycogen synthase kinase-3β 
(GSK3β), HIPK2 and DYRK2, have been shown to phosphorylate p53 after DNA damage. So 
far, 17 phosphorylation/dephosphorylation sites have been detected following DNA damage 
induced by ionizing radiation or ultraviolet (UV)-light irradiation. In humans, these sites 
include Ser6, 9, 15, 20, 33, 37 and 46, and Thr18 and 81 in the amino-terminal region; Ser315 
and Ser392 in the C-terminal domain; and Thr150, Thr155 and Ser215 in the central core. In 
addition, Thr55, Ser376 and Ser378 seem to be constitutively phosphorylated in unstressed 
cells (Gatti, Li et al. 2000) (Fig. I). Only a few p53 sites are reported to be phosphorylated by 
one specific protein kinase. Clearly, significant redundancies are observed, yet this 
multiplicity may provide a failsafe mechanism and a distinctive combination of 
phosphorylated residues could be required for further modifications, leading to maximal 
activation.  
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Fig. I: Schematic representation of p53 phosphorylation sites and the enzymes involved in p53 phosphorylation
upon different stimuli  
 
 
The phosphorylation of the amino-acid residues Ser15, Thr18 and Ser20 in the N-terminal 
domain of human p53 are the most extensively studied. These residues are located in, or close 
to, the region of p53 that also binds to MDM2/MDMX (Appella and Anderson 2001; Ito, Lai 
et al. 2001; Sabbatini and McCormick 2002; Bode and Dong 2004). Ser15 is  phosphorylated 
in an ATM-dependent manner early in response to γ-irradiation (Banin, Moyal et al. 1998; 
Waterman, Stavridi et al. 1998), being ATR the kinase responsible for Ser15 phosphorylation 
upon UV radiation (Tibbetts, Brumbaugh et al. 1999). Also p38 phosphorylates p53 at this 
residue in response to UV radiation (Bulavin, Saito et al. 1999). Data from in vitro or 
overexpression studies indicate that phosphorylation at Ser15 stimulates p53-dependent 
transactivation, growth arrest and apoptosis in response to DNA damage (Fiscella, Ullrich et 
al. 1993; Shieh, Ikeda et al. 1997). However, there exist conflicting data on whether Ser15 
phosphorylation affects MDM2 binding or not (Shieh, Ikeda et al. 1997; Dumaz and Meek 
1999), but it is known that it increases the interaction with the acetyltransferase CBP 
(Lambert, Kashanchi et al. 1998). Phosphorylation of other residues, including Thr18 and 
Ser20, which occurs later in the response to DNA damage, was shown to depend on initial 
phosphorylation at Ser15 and seems to interfere with the interaction of p53 with MDM2, thus 
promoting p53 stabilization (Chehab, Malikzay et al. 1999; Dumaz, Milne et al. 1999; Unger, 
Juven-Gershon et al. 1999).  
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Phosphorylation of Ser46 by the kinases HIPK2, p38 and DYRK2 was reported to mediate 
selectivity in promoter binding by p53 and to specifically promote the induction of apoptosis 
inducing genes, such as p53-regulated apoptosis-inducing protein1 (p53AIP1) (Oda, Arakawa 
et al. 2000; D'Orazi, Cecchinelli et al. 2002; Taira, Nihira et al. 2007). Moreover, HIPK2-
mediated phosphorylation of p53 at Ser46 is required for the acetylation of p53 at Lys382 by 
CBP (Hofmann, Moller et al. 2002). Phosphorylation at Ser46 is sufficient for p53 to induce 
the PTEN tumor suppressor protein relative to MDM2 (Mayo, Seo et al. 2005). The shift of 
p53 gene targeting from MDM2 to PTEN results in sustained p53 activation and diminished 
survival as p53 and PTEN coordinate cell death by facilitating one another’s expression and 
functions. 
Moreover, under normal conditions p53 represses its own phosphorylation at Ser46 due to 
MDM2-mediated HIPK2 degradation (Rinaldo, Prodosmo et al. 2007). This creates another 
positive feedback loop in which MDM2 degrades HIPK2 thus decreasing p53 
phosphorylation at Ser46. Under these conditions p53 will activate MDM2 transcription 
rather than PTEN. These findings support the notion that the cell-cycle-arresting functions of 
p53 include active inhibition of the apoptotic ones, and furthermore indicates that 
phosphorylation at Ser46 is an important determinant of p53 choice as it acts like a switch 
between two opposite feedback loops. 
Within the DNA binding domain, Ser215 phosphorylation by Aurora Kinase A abolishes the 
DNA binding ability of p53 (Liu, Kaneko et al. 2004); Thr150 and Thr155 are phosphorylated 
by two COP9 signalosome-associated kinases, CK2 and protein kinase D, leading to 
ubiquitin-dependent degradation of p53 (Uhle, Medalia et al. 2003). Interestingly, a recent 
report demonstrated that Ser149 of p53 is O-GlcNAcylated and that this modification is 
associated with decreased phosphorylation of p53 at Thr155, resulting in decreased p53 
ubiquitylation (Yang, Kim et al. 2006). This offers another demonstration of the dynamic 
interplay between different post-translational modifications in p53. 
With respect to the CT-domain, phosphorylation of p53 at serine 315 and serine 376, by GSK-
3β upon ER stress, has been shown to increase its cytoplasmic localization and reduce its 
stability (Qu, Huang et al. 2004; Qu and Koromilas 2004; Pluquet, Qu et al. 2005). 
Phosphorylation of Ser315 by the cyclinB-dependent kinase p34(Cdc2), was reported to 
increase the transactivation potential of human p53 in response to radiation damage, possibly 
by promoting nuclear retention, mediated via interaction of p53 with E2F1 (Blaydes, Luciani 
et al. 2001; Fogal, Hsieh et al. 2005). Phosphorylation at the same site by aurora kinase A, 
however, was suggested to promote MDM2-dependent ubiquitylation and proteolysis of p53, 
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arguing for an inhibitory role of this modification (Katayama, Sasai et al. 2004). Ser392 is 
phosphorylated by p38 or CK2 in response to UV-irradiation, but only very inefficiently after 
γ-irradiation. An UV-activated protein kinase complex that phosphorylates Ser-392 of p53 in 
vitro has been identified. This kinase complex contains CK2 and the chromatin transcriptional 
elongation factor FACT (a heterodimer of hSpt16 and SSRP1). FACT seems to alter the 
specificity of CK2 in the complex such that it selectively phosphorylates p53 over other 
substrates including casein. Phosphorylation by the kinase complex enhances p53 activity 
(Keller, Zeng et al. 2001). It has been demonstrated that damage-stimulated phosphorylation 
of p53 at Ser392 by CK2 has an important impact on p53 structure as it can increase intrinsic 
thermostability of the core DNA-binding domain thus enhancing p53 affinity for its consensus 
DNA binding site.  
In addition to stress-induced phosphorylation there are also a few sites in p53 which are 
dephosphorylated in response to stress signals, such as Ser376 and Thr55. The loss of 
phosphorylation from Ser376 creates a consensus binding site for 14-3-3σ and in turn 
increases the affinity of p53 for sequence-specific binding sites on DNA (Waterman, Stavridi 
et al. 1998). Dephosphorylation by PP2A at Thr55 instead has been shown to stabilize p53 
(Li, Cai et al. 2007). It is likely that an ordered pattern and interdependence of stress-induced 
modifications to p53 exist in cells. However, the relevance and the precise role of 
phosphorylation on p53 in its stabilization and activation remain controversial. While it seems 
likely that the complex network of stress-induced modifications to p53 is important in 
generating a functional molecule, there is also evidence that p53 can be activated without 
these changes. It was demonstrated that p53 stabilization occurs as well upon mutation of a 
series of known stress-induced phosphorylation sites (Fuchs, O'Connor et al. 1995; Blattner, 
Tobiasch et al. 1999). Further evidence pointing to a lack of requirement for post-translational 
modification in p53 stabilization comes from the use of small molecule inhibitors of the p53–
MDM2 interaction. In fact, p53 accumulates in cells treated with Nutlin-1 (a cis-imidazoline 
analogue that displaces p53 from its complex with MDM2) and this is followed by an increase 
in the levels of both p21 and MDM2 consistent with activation of the p53 pathway. Yet, 
unlike DNA damage, nutlins did not induce phosphorylation of p53 but stabilized, 
unphosphorylated form of p53 which was equally efficient at sequence-specific DNA binding 
and induction of apoptosis (Thompson, Tovar et al. 2004). 
These controversial results does not mean, however, that phosphorylations on p53 are 
irrelevant or do not occur in vivo; nature appears to be able to compensate quite easily for the 
loss of one or even two or more of these modifications in p53.  
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- Acetylation 
 
p53 can be acetylated at several lysines by different HAT (Fig. J). Acetylation of p53 by 
p300/CBP and PCAF occurs in response to DNA damaging agents, such as UV- and γ-
irradiation. CBP and p300 acetylate p53 at lysines within the C-terminal domain (Lys370, 
372, 373, 381, 382) (Avantaggiati, Ogryzko et al. 1997; Gu and Roeder 1997; Lill, Grossman 
et al. 1997). Moreover, Lys320 and Lys305 in the nuclear localization domain are acetylated 
by PCAF (p300/CBP-associated factor) and p300, respectively (Sakaguchi, Herrera et al. 
1998; Liu, Scolnick et al. 1999). Finally, the MYST family acetyl transferases, hMOF and 
TIP60, were recently shown to acetylate p53 at Lys120 in the DBD (Legube, Linares et al. 
2002; Berns, Hijmans et al. 2004; Doyon, Selleck et al. 2004). 
 
 
Fig. J: Schematic representation of post-translational modifications occurring on p53 at Lysine residues.
Ac, acetylation; M, methylation; Ub, ubiquitylation; N, NEDDylation; SU, sumoylation. The enzymes 
mediating the modification are indicated.  
 
 
The role of acetylation in mediating p53 binding to DNA has been largely debated and is still 
controversial (Gu and Roeder 1997) yet, what is commonly accepted is that it potentiates the 
recruitment of co-factors thus favoring p53 transcriptional activation. 
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Consistently, reports showing that acetylated p53 is enriched at target promoters in a stress 
dependent manner (Liu, Xia et al. 2003; Mantovani, Tocco et al. 2007) suggest a role for p53 
acetylation in affecting its transcriptional activation. While some studies could show that 
acetylation favours the recruitment of co-factors and histone acetyltransferases (TTRAP and 
CBP), thus increasing p53 transcriptional activity (Barlev, Liu et al. 2001), other suggested 
that the enhancing effect of p300/CBP on p53 transactivation function was independent of 
p53 acetylation (Espinosa and Emerson 2001).   
Nevertheless, a number of recent studies indicate that acetylation of specific lysine residues 
on p53 has differential effects on the choice of the target genes induced by p53. Using 
acetylation-mimicking lysine to glutamine mutations, functional differences between 
acetylation of Lys320 versus Lys373 were reported. Acetylation of Lys320 in p53 was shown 
to favour interaction with high-affinity p53-binding sites in target genes, promoting cell 
survival and cell cycle arrest. In contrast, acetylation of Lys373 led to a stronger interaction of 
p53 with low-affinity binding sites, which are found in pro-apoptotic target genes and 
therefore promoted cell death (Knights, Catania et al. 2006). 
Acetylation on Lys120 by the MYST family acetyl transferase Tip60 has also been shown to 
modulate p53 transcriptional activity and to be necessary for apoptotic response. Notably, 
Lys120 is specifically acetylated by Tip60 (Legube, Linares et al. 2004). Lys120-acetylated 
p53 was reported to accumulate upon DNA damage preferentially on the promoters of pro-
apoptotic target genes, including Bax and PUMA. 
Acetylation might also enhance p53 transcriptional activity through promoting the assembly 
of an active transcriptional apparatus. It is known that TFIID binding to the core promoter 
element is required for assembly of a functional transcriptional initiation complex (Thomas 
and Chiang 2006). TAF1, the larger subunit of TFIID has been shown to interact with the C-
terminal domain of p53 on p21 promoter (Espinosa, Verdun et al. 2003; Li and Wu 2004).  In 
a recent study it has been demonstrated that the acetylation of two lysine residues in p53, 
Lys373 and Lys382, leads to a direct interaction with the Double Bromodomain (DBrD), a 
structural protein module that recognizes acetylated lysines of TAF1 to induce the 
transcription of p21. Notably, also the recruitment of CBP is mediated through the binding of 
its single bromodomain to p53 acetylated on Lys382 (Mujtaba, He et al. 2004). Recruitment 
of HATs has been shown both to enhance p53 acetylation and to favour the acetylation of 
histones on p53 responsive promoters thus favouring transcriptional activation.  
Interestingly, it has been proposed that DNA-binding is required to allow p53 acetylation by 
p300; in its absence the C-terminal domain of p53 is not accessible for acetylation by p300 
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and this provides an intrinsic negative regulatory mechanism to prevent acetylation until the 
tetramer is promoter bound. After DNA binding, allosteric effects mediate an exposure of the 
acetylation motif to allow DNA-dependent acetylation of the tetramer. Notably, the 
conformational change allows p300 to contact p53 on its PRD and this interaction is essential 
for DNA-dependent acetylation of p53 (Dornan, Shimizu et al. 2003). Indeed, upon PRD 
deletion, p300 can still bind to p53 on its N-terminal LXXLL motif encompassing Thr18-
Ser20, but cannot acetylate DNA-bound p53. It has been suggested that the prolyl-isomerase 
Pin1 may assist structural rearrangements that occur upon DNA binding thus promoting the 
DNA-dependent acetylation of p53 by p300. This may occur at least in part through 
phosphorylation induced isomerization of Thr81-Pro82 within the PRD. Indeed, it has been 
demonstrated that mutations affecting this site, result in impaired acetylation of p53 at Lys 
373 and Lys382 (Mantovani, Tocco et al. 2007). Moreover, Pin1-mediated Pro82 
isomerization within the PRD has been shown to be required for Ser20 phosphorylation by 
Chk2 (Berger, Stahl et al. 2005), which promotes p53 binding to p300 (Dornan and Hupp 
2001). DNA-dependent acetylation of p53 stabilizes p300 binding (Dornan, Shimizu et al. 
2003) and directs the organization of transcription complexes on the p53 bound promoters 
thus promoting the transcriptional functions of p53. 
The acetylation status of p53 can be regulated via deacetylation by an HDAC1 (histone 
deacetylase 1)-containing complex (Murphy, Ahn et al. 1999) or by the NAD-dependent 
histone deacetylase SIRT1 (silent information regulator 2a, Sir2a) (Vaziri, Dessain et al. 
2001). Moreover, overexpression of HDAC1, 2 and 3 repress p53 transcription (Juan, Shia et 
al. 2000). Deacetylation was shown to repress p53-dependent transcriptional activation, 
apoptosis and growth arrest (Luo, Su et al. 2000; Luo, Nikolaev et al. 2001). Moreover, as the 
lysine residues within the CTD of p53 are also targets for ubiquitylation, it was proposed that 
acetylation of these residues may promote the stabilization of p53 by interfering with 
proteasomal degradation (Brooks and Gu 2003). In addition to mediating p53 ubiquitylation, 
MDM2 also seems to interfere with the acetylation of p53. Indeed, it was shown to inhibit p53 
acetylation by p300 and PCAF (Ito, Lai et al. 2001; Jin, Zeng et al. 2002) and to promote the 
HDAC1-mediated deacetylation of p53 (Ito, Kawaguchi et al. 2002). It has been observed that 
many tumor-associated proteins can mediate p53 deacetylation; the oncogenic form of PML, 
PML-RAR (Insinga, Monestiroli et al. 2004), and the metastasis-associated MTA2/PID (Luo, 
Su et al. 2000), have been shown to recruit HDACs to exert their negative control on p53 
function.  
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- Other modifications 
 
Lysine residues are also targeted by methyl transferases (Fig. J). Methylation of p53 can occur 
at least at two different sites, leading to opposite effects on p53 function. Methylation at 
Lys372 by the methyl-transferase Set9, increases the stability of p53, restricts it to the nucleus 
and enhances p53 dependent transcription, whereas methylation of Lys370, mediated by 
another methyl transferase, Smyd2, leads to repression of transcriptional activity (Chuikov, 
Kurash et al. 2004; Huang, Perez-Burgos et al. 2006). In human cells, the histone lysine-
specific demethylase LSD1 interacts with p53 to repress p53-mediated transcriptional 
activation and to inhibit the role of p53 in promoting apoptosis (Huang, Sengupta et al. 2007). 
While in vitro LSD1 removes both monomethylation (K370me1) and dimethylation 
(K370me2) at K370, in vivo, LSD1 shows a strong preference to reverse K370me2, which is 
performed by an unknown methyltransferase, distinct from Smyd2. Interestingly, methylation 
at K370me2 has a different role in regulating p53 from that of K370me1: K370me1 represses 
p53 function, whereas K370me2 promotes association with the co-activator 53BP1 (p53-
binding protein 1) through tandem Tudor domains in 53BP1. Thus, LSD1 represses p53 
function through the inhibition of interaction of p53 with 53BP1. Taken together, these 
observations show that p53 is dynamically regulated by lysine methylation and demethylation 
and that the methylation status at a single lysine residue confers distinct regulatory outputs.  
Lysine residues are also subjected to other post-translational modifications such as 
ubiquitylation, sumoylation and NEDDylation (Fig. J). p53 is ubiquitinated by several E3 
ubiquitin-ligases among which MDM2 is the best characterized (see above). MDM2 can 
induce both monoubiquitylation of p53, leading to nuclear export (Gu, Nie et al. 2001) and 
mitochondrial localization (Marchenko, Wolff et al. 2007), and polyubiquitylation that leads 
to degradation by the 26S proteasome (Li, Brooks et al. 2003). 
Three lysines targeted for ubiquitination (Lys 370, Lys372 and Lys373) are also subjected to 
NEDDylation. The C-terminal glycine residue of the ubiquitin-like protein NEDD8 is 
covalently linked to p53 by MDM2 thus inducing transcriptional repression (Xirodimas, 
Saville et al. 2004). Sumoylation is also similar to ubiquitylation in that an isopeptide bond is 
formed between the C-terminal carboxy group of the small ubiquitin-like protein SUMO1 and 
the ε-amino group of Lys386 (Gostissa, Hengstermann et al. 1999; Rodriguez, Desterro et al. 
1999). Sumoylation was reported to positively modulate p53 transcriptional activity (Gostissa, 
Hengstermann et al. 1999; Rodriguez, Desterro et al. 1999). Other data indicate that 
sumoylation of p53 has a repressive effect (Buschmann, Fuchs et al. 2000; Chen and Chen 
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2003), leaving the issue of whether sumoylation of p53 results in activation or repression of 
p53 activities controversial. Although the effect on p53 is not completely elucidated, several 
other key regulators of p53 activation are subjected to sumoylation, including PML, MDM2, 
HIPK2 and p300 (Kim, Choi et al. 1999; Xirodimas, Chisholm et al. 2002; Girdwood, 
Bumpass et al. 2003). In particular sumoylation of PML is important in the formation of the 
nuclear bodies (Ishov, Sotnikov et al. 1999). 
 
b.3) Regulation of p53 by localization at PML-NBs 
 
The promyelocytic leukaemia protein (PML) is a tumor suppressor originally identified in 
acute promyelocytic leukaemia patients with a reciprocal t(15;17) chromosomal translocation 
where PML is fused to the retinoic acid receptor-α (RARα) gene (Kakizuka, Miller et al. 
1991; Melnick and Licht 1999; Bernardi and Pandolfi 2003). PML localizes to and is 
responsible for the formation of punctuate nuclear structures that are interspersed between 
chromatin, known as PML nuclear bodies (PML-NBs) (Ishov, Sotnikov et al. 1999; Salomoni 
and Pandolfi 2002). PML-NBs are discrete nuclear foci, 0,2-1,0 µm wide, that are present in 
most mammalian cell nuclei and typically number 1-30 bodies per nucleus, depending on the 
cell type, cell-cycle phase and differentiation stage (Dellaire and Bazett-Jones 2004).  
Many proteins reside constitutively, but more often transiently, in PML-NBs. Consequently, 
PML-NBs have been implicated in the regulation of various cellular functions, such as the 
induction of apoptosis and cellular senescence, inhibition of proliferation, maintenance of 
genomic stability and antiviral responses (Bernardi and Pandolfi 2007). Althoug the 
physiological roles of PML and PML-NBs are still a matter of debate, their tumor suppressive 
role is common to all of these functions (Salomoni and Pandolfi 2002). Furthermore, PML-
NBs and their implicated functions are frequently lost in both leukaemias and solid tumors 
(Koken, Linares-Cruz et al. 1995; Gambacorta, Flenghi et al. 1996; Gurrieri, Capodieci et al. 
2004). 
Among the proteins that localize in PML-NBs are p53 and several of its regulators, including 
acetyltransferases, deacetylases, MDM2 and small ubiquitin-like modifier 1 (SUMO1). 
Several studies suggested that PML is an upstream regulator of p53. pml-/- thymocytes are 
severely impaired in p53 transcriptional activity and p53 dependent apoptosis (Guo, Salomoni 
et al. 2000). In addition, cells derived from pml-/-  mice are resistant to ionizing radiation-
induced apoptosis (Wang, Ruggero et al. 1998). Conversely, p53-deficient cells are resistant 
to PML-induced arrest and apoptosis (de Stanchina, Querido et al. 2004), and after DNA 
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damage PML recruits p53 to PML-NBs which coincides with the increased transcription of 
p53 targets (Guo, Salomoni et al. 2000). This is thought to be due, in part, by the ability of 
PML to recruit CBP to PML-NBs which thereafter prompts p53 acetylation (Guo, Salomoni 
et al. 2000; Boisvert, Kruhlak et al. 2001). Interestingly, it was observed that only PML IV 
(PML3) isoform is able to regulate positively p53 through p53 binding (Fogal, Gostissa et al. 
2000). PML is modified by SUMO and the formation of PML-NBs is regulated by this 
modification (Duprez, Saurin et al. 1999; Shen, Lin et al. 2006). SUMO modified PML results 
in transactivation and strong recruitment of p53 to NBs (Gostissa, Hengstermann et al. 1999). 
However, SUMO modification of PML or p53 is not required for colocalization or interaction. 
Instead, SUMO modification appears to be necessary for the observed PML dependent 
increase in transactivation of p53 (Gostissa, Hengstermann et al. 1999; Fogal, Gostissa et al. 
2000). These findings, suggest that recruitment of p53 to NBs alone is insufficient for its 
activation, but that a second, NB dependent, event is required. 
Moreover, PML can bind to MDM2 and p53 (Kurki, Latonen et al. 2003; Wei, Yu et al. 2003; 
Zhu, Wu et al. 2003), consequently stabilizing p53 by preventing MDM2-mediated p53 
ubiquitylation and degradation (Kurki, Latonen et al. 2003; Louria-Hayon, Grossman et al. 
2003), and sequestering MDM2 within the nucleolus after DNA damage (Bernardi, Scaglioni 
et al. 2004). 
HIPK2 interacts with both p53 and CBP, and is also recruited to PML-NBs after DNA 
damage, favoring p53 acetylation and transcriptional activity (D'Orazi, Cecchinelli et al. 
2002; Moller, Sirma et al. 2003). 
As was mentioned above, PML was originally implicated in the induction of senescence 
because it is transcriptionally induced upon overexpression of the Ras-V12 oncogene and 
because it facilitates p53 activation by mediating its acetylation. 
More recently, the PML gene was shown to be p53-responsive, suggesting that PML is an 
integral component of the p53 response, and indeed may act in a positive feedback loop (de 
Stanchina, Querido et al. 2004), contributing to the tumor suppressor functions of p53, 
including p53-mediated senescence, cell-cycle arrest and apoptosis. The precise mechanisms 
by which PML mediates these effectors functions are still to be determined, however it is 
quite clear that PML is a crucial component in the p53 functional network.  
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c) p53 cellular functions 
 
There are three main outcomes after the activation of p53: apoptosis, senescence or cell-cycle 
arrest. The first two are terminal for the cell, whereas cell-cycle arrest permits repair 
processes to act and damage to be reversed, so that the cell survives. How the choice can be 
driven toward a specific response depends on different factors. First, the induction of p53 
activation has different outcomes depending on cell type. In primary fibroblasts it is in fact 
usually associated with cell cycle arrest and senescence (Kuerbitz, Plunkett et al. 1992; Di 
Leonardo, Linke et al. 1994) whereas the activation of p53 in hematopoietic cells (e.g., 
thymocytes) generally results in apoptosis (Lowe, Schmitt et al. 1993). Moreover, even within 
a particular cell type, the p53 response can be influenced by many factors such as the nature 
of the stimuli that activate p53 and a plethora of protein partners that affect its stability and 
activity. 
 
c.1) Cell-cycle arrest and DNA damage repair  
 
The ability of p53 to induce cell-cycle arrest mostly depends on three critical target genes: 
p21, 14-3-3σ and GADD45 (Kastan, Zhan et al. 1992; el-Deiry, Tokino et al. 1993; 
Hermeking, Lengauer et al. 1997). The cyclin-dependent kinase inhibitor p21Waf1/Cip1 was the 
first transcriptional target identified and its transactivation results in cell cycle arrest in G1 
phase due to inhibition of cyclinE/CDK2, cyclinA/CDK2 and cyclinD/CDK4 (Harper, Adami 
et al. 1993; Prives and Hall 1999), that leads to an accumulation of hypophosphorylated Rb 
that in turn binds and inhibits the transcription function of E2F1, blocking the S-phase entry 
and consequently the cell-cycle progression. The role of p21 in G1-arrest is further underlined 
by the observation that cells lacking p21 fail to arrest in response to DNA-damage, yet they 
can still undergo cell death (Brugarolas, Chandrasekaran et al. 1995). Although the most 
prominent function of p21 is the mediation of G1 arrest, evidence has been presented that it 
also participates in the G2/M arrest after DNA damage, presumably by blocking PCNA 
function at replication forks (Bunz, Dutriaux et al. 1998; Ando, Kawabe et al. 2001). 
However, the p53-induced G2 arrest is mostly mediated by the activation of genes such as 
GADD45 and 14-3-3σ. 14-3-3σ has been shown to prevent nuclear import of cyclinB1 and 
CDC2, through their sequestration in the cytoplasm (Chan, Hermeking et al. 1999), whereas 
GADD45 destabilizes CDC2/cyclinB complexes and these two processes cooperate to prevent 
initiation of mitosis (Zhan, Antinore et al. 1999; Jin, Tong et al. 2002). 
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Part of tumor suppressor functions of p53 is exerted by preventing propagation of deleterious 
mutations arising from DNA damage. Indeed, p53 plays an indirect role also in DNA repair 
through the induction of ribonucleotide reductase subunits (Hwang, Ford et al. 1999; Xue, 
Zhou et al. 2003). Another p53-regulated gene, GADD45, that was originally proposed to 
participate in global genomic repair downstream of p53 (Smith, Chen et al. 1994) has been 
later reported to have more likely functions in remodelling chromatin to give access to the 
sites of damaged DNA (Smith, Ford et al. 2000). Furthermore, two mismatch repair genes 
MLH1 and PMS2 have recently been shown to contain p53-response elements within their 
first intron and to be responsive to p53 activation after DNA-damage. These two genes may 
provide a sensor in DNA repair mechanisms and constitute a critical determinant for the 
decision between cell-cycle arrest and apoptosis (Chen and Sadowski 2005). 
A direct participation of p53 in DNA repair was suggested by a number of biochemical 
observations. For instance, the C-terminal 30 amino acids of p53 were shown to recognise 
several DNA damage-related structures, such as DNA ends, gaps, and insertion/deletion 
mismatches (Bakalkin, Selivanova et al. 1995; Jayaraman and Prives 1995; Lee, Elenbaas et 
al. 1995). p53 was also demonstrated to catalyze reannealing of short stretches of single- and 
double-stranded DNA and to promote strand exchange between them (Oberosler, Hloch et al. 
1993; Brain and Jenkins 1994). In addition to p53’s biochemical activities, numerous reports 
on physical and functional protein interactions further strengthened the proposal of a direct 
role of p53 in nucleotide excision repair (NER), base excision repair (BER), and double-
strand break (DSB) repair (Albrechtsen, Dornreiter et al. 1999; Bertrand, Saintigny et al. 
2004).  
Although it is well documented that efficient nucleotide excision repair (NER) requires p53, 
its exact role has been difficult to define (Hanawalt 2001). It has been suggested that p53 may 
function in NER by facilitating access to the chromatin to the repair machinery thus favoring 
DNA repair. It was further demonstrated that p53 is required for global chromatin relaxation 
induced by UV-irradiation (Rubbi and Milner 2003). In concordance with this, the histone 
deacetylase inhibitor trichostatin A overcomes the requirement for p53 suggesting that p53 
may induce global chromatin relaxation through changes in histone acetylation (Rubbi and 
Milner 2003). Moreover, the histone acetyltransferase p300 binds and co-localizes with p53 to 
sites of NER and inhibition of p300 by antibody microinjection inhibits NER, suggesting that 
p53-dependent recruitment of p300 histone acetyl-transferase (HAT) activity may be 
mechanistically involved in the ability of p53 to induce global chromatin relaxation to foster 
DNA repair (Rapic-Otrin, McLenigan et al. 2002). 
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p53 is also directly involved in inhibiting homologous recombination (HR). Two studies 
demonstrated that p53 inhibits HR in response to replication fork stalling (Janz and 
Wiesmuller 2002; Saintigny and Lopez 2002). Consistently, it was further noticed that p53 
prevents the accumulation of DSBs at stalled-replication forks induced by UV or hydroxyurea 
treatment (Kumari, Schultz et al. 2004; Squires, Coates et al. 2004). When DNA replication is 
blocked, p53 becomes phosphorylated on serine 15 and associates with key enzymes of HR 
(Zink, Mayr et al. 2002; Linke, Sengupta et al. 2003; Sengupta, Linke et al. 2003). Notably, 
during replication arrest p53 remains inactive in transcriptional transactivation (Gottifredi, 
Shieh et al. 2001; Restle, Janz et al. 2005) supporting the idea that p53 is involved in HR 
regulatory functions unrelated to transcriptional activities. 
 
c.2) Apoptosis 
 
Clearly the main role of p53 is to prevent the outgrowth of damaged or stressed cells that may 
develop into malignancies if left unchallenged. This can be achieved by eliminating any 
aberrant cells through apoptosis. Indeed, the best known transcriptional targets of p53 include 
a large number of pro-apoptotic genes that can be divided into several categories depending 
on their specific functions. These target genes are generally classified on the basis of their 
involvement either in the extrinsic or in the intrinsic apoptotic pathway. The extrinsic 
apoptotic pathway is triggered upon the engagement of particular death-receptors belonging to 
TNF-receptor family to their specific ligands and leads to the induction of a cascade of 
caspase activation which in turn induces apoptosis (Nagata and Golstein 1995; Wu, Burns et 
al. 1997; Attardi, Reczek et al. 2000). The intrinsic pathway instead is activated in response to 
different signals such as DNA damage, oncogenic signalling, hypoxia or endoplasmic 
reticulum stress, and is associated with mitochondrial depolarization and release of 
cytochrome c (cyt c) from the mitochondrial intermembrane space into the cytoplasm. This 
event leads to the formation of the apoptosome, a complex of cyt c, APAF-1 and pro-caspase-
9, that activates the caspase cascade, thus converging in the effector phase with the extrinsic 
pathway (Cory and Adams 2002). 
p53 can promote apoptosis via the extrinsic pathway by activating the transcription of the 
death receptors located at the plasma membrane, including Fas, DR4 and KILLER/DR5, 
PERP and PIDD. Both DR5 and DR4 can trigger apoptosis or enhance apoptosis induced by 
their ligand TRAIL and by chemotherapeutic agents (Liu, Yue et al. 2004). Fas can be 
activated by p53, yet its induction upon DNA damage is tissue specific and often does not 
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require p53 (Bouvard, Zaitchouk et al. 2000). Moreover, Fas is dispensable for p53-dependent 
apoptosis in most tissues (O'Connor, Harris et al. 2000). PERP, a PMP-22/gas family protein, 
is activated in transformed MEFs following DNA damage (Attardi, Reczek et al. 2000) and 
contributes to the p53-dependent apoptosis induced by γ-irradiation in thymocytes and 
neurons, but not to that induced by oncogene activation (Ihrie, Reczek et al. 2003; Reczek, 
Flores et al. 2003). PIDD was identified as a p53-regulated gene in mouse erythroleukemia 
cells and shown to promote apoptosis. Its induction by ionizing radiation is p53-dependent 
also in MEFs (Lin, Ma et al. 2000). It  has been described that PIDD can form an activating 
complex with caspase 2 (Tinel and Tschopp 2004). Yet, it remains unclear whether PIDD is 
required for p53-dependent apoptosis as caspase 2 deficiency does not abrogate p53 responses 
in vivo.  
Several other p53-regulated genes such as Bax, Noxa and PUMA enhance the release of Cyt c 
into cytoplasm from mitochondria to initiate the intrinsic apoptotic pathway. Bax was the first 
identified p53-regulated pro-apoptotic Bcl-2 family member (Miyashita and Reed 1995). Loss 
of Bax accounts for nearly half of the accelerated tumor growth which resulted from the loss 
of p53 in a brain tumor model (Schmitt, Fridman et al. 2002). Bax is also responsible for 
nearly half of p53-dependent apoptosis induced by 5-FU in colorectal cancer cells (Zhang, Yu 
et al. 2000). Nevertheless, Bax is dispensable for the apoptosis induced by γ-irradiation in 
thymocytes and intestinal epithelial cells and its induction is not strictly dependent on p53 in 
many tissues (Bouvard, Zaitchouk et al. 2000). 
p53 regulates the expression of several BH3 domain-only proteins that function upstream of 
Bax to induce apoptosis. Some of these proteins are shown to be critical mediators of p53-
dependent apoptosis. PUMA and Noxa are activated in a p53-dependent manner following 
DNA damage (Han, Flemington et al. 2001; Nakano and Vousden 2001; Yu, Zhang et al. 
2001). PUMA mediates apoptosis induced by p53 in response to hypoxia, DNA damaging 
agents, and endoplasmic reticulum (ER) stress in human colorectal cancer cells (Reimertz, 
Kogel et al. 2003; Yu, Wang et al. 2003). Remarkably, PUMA-knockout mice recapitulated 
several key apoptotic deficiencies observed in the p53-knockout mice, including deficiencies 
in the apoptosis induced by γ-irradiation in thymocytes, by oncogenes in MEFs, and by DNA 
damage in developing neurons (Jeffers, Parganas et al. 2003; Villunger, Michalak et al. 2003). 
This suggests that the ability of PUMA to mediate apoptosis and tumor suppression is 
context-dependent. Indeed, other studies demonstrated that the capability of PUMA to act as a 
tumor suppressor can be dependent on other oncogenic events such as myc or E1A activation. 
Notably, PUMA depletion cooperated with myc and E1A induced tumorigenesis but not with 
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Ras as this last oncogene induces a senescence response rather than apoptosis. Similarly, 
Noxa-deficient mice develop normally but their MEFs are strongly resistant to apoptosis 
induced by oncogenes and UV radiation while only slightly resistant to etoposide induced cell 
death. In vivo, the absence of Noxa resulted in resistance to X-ray-induced apoptosis in the 
small intestinal crypts (Shibue, Takeda et al. 2003; Villunger, Michalak et al. 2003). 
Moreover, p53 contributes to the formation of the apoptosome also through the transcriptional 
activation of APAF-1 (Kannan, Kaminski et al. 2001; Moroni, Hickman et al. 2001) and is 
involved in the more downstream phases of apoptosis by activating the transcription of 
caspase-6 (MacLachlan and El-Deiry 2002). 
p53 may sense the alterations in ROS levels and can activate numerous REDOX genes like 
PIG3, POX2/PIG6 and ferredoxin reductase (Donald, Sun et al. 2001; Hwang, Bunz et al. 
2001). This results in an increased generation of ROS and originates a positive loop feeding 
p53 activation that further contributes to apoptosis (Johnson, Yu et al. 1996; Polyak, Xia et al. 
1997; Li, Dietz et al. 1999; Martindale and Holbrook 2002). Moreover, p53 can contribute to 
the apoptotic pathway also through repressing the transactivation of anti-apoptotic genes such 
as Bcl-2 (Haldar, Negrini et al. 1994; Miyashita, Harigai et al. 1994; Miyashita, Krajewski et 
al. 1994), Bcl-XL (Cherbonnel-Lasserre and Dosanjh 1997) and survivin (Hoffman, Biade et 
al. 2002). 
Interestingly, p53 appears also to provide a connection between the extrinsic death receptor 
pathway and the triggering of mitochondrial disruption processes through the activity of its 
transcriptional target Bid. In fact Bid is activated by caspase-8 upon triggering of the extrinsic 
pathway and translocates to the mitochondria where it activates Bax and consequently the 
initiation of the intrinsic pathway (Sax, Fei et al. 2002). Among the pro-apoptotic p53 target 
proteins Scotin (Bourdon, Renzing et al. 2002), that is located in the ER and the nuclear 
membrane, has been shown to be required for ER-stress mediated apoptosis. As a protein-
folding compartment, the ER is extremely sensitive to alterations in homeostasis that disrupt 
its functions (Kaufman 1999; Ferri and Kroemer 2001). Prolonged ER stress can result in the 
activation of caspase-12 that in turn activates caspase-9 thus executing apoptosis. It has been 
proposed that, upon ER-stress, the release of calcium from the ER triggers mitochondrial 
depolarization thus allowing the release of Cyt c to the cytosol and the activation of the 
caspase cascade (Ichas, Jouaville et al. 1997; Ichas and Mazat 1998; Jouaville, Ichas et al. 
1998). Notably, upon ER-stress p53 is up-regulated and induces transcription of two other 
pro-apoptotic genes, Noxa and PUMA (Li, Lee et al. 2006). These evidences clearly suggest 
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that p53 mediates the apoptotic response at multiple levels and that the apoptotic pathways are 
not independent but rather involved in a complex interplay.                                                                            
p53 participates in apoptosis also in a transcription-independent fashion by acting directly at 
mitochondria where it can perturb or modulate the functions of proteins implicated in the 
apoptotic machinery. This was thought to account for the reported ability of a transactivation 
incompetent p53 mutant to trigger apoptosis via the mitochondrial death pathway (Regula and 
Kirshenbaum 2001). A fraction of p53 protein rapidly translocates to mitochondria in 
response to genotoxic, hypoxic, and oxidative stresses (Marchenko, Zaika et al. 2000) and it 
has recently been demonstrated that this translocation is dependent on its monoubiquitination 
by MDM2 (Marchenko, Wolff et al. 2007). At the mitochondria, p53 has been found to 
interact with the Bcl-XL and Bcl-2 protective proteins and to prevent them from inhibiting on 
the oligomerization among Bax and Bak (Mihara, Erster et al. 2003). There is a crosstalk 
among p53 functions at the mitochondria and its transcriptional activity, in fact upon stress-
induced stabilization and activation within the nucleus, p53 induces the transcription of 
PUMA and this one is able to release cytoplasmic p53 from the inhibitory interaction with 
Bcl-XL, thus allowing it to directly activate Bax (Chipuk, Bouchier-Hayes et al. 2005). p53 
interacts also with Bad and the mitochondrial p53/Bad complex promotes apoptosis via 
activation and oligomerization of Bak (Jiang, Du et al. 2006). Moreover, p53 acts directly on 
the pro-apoptotic Bak promoting its dissociation from the anti-apoptotic protein MCL1 (Leu, 
Dumont et al. 2004). Once the inhibitory interactions upon Bax and Bak are relieved, they 
oligomerize to form a transmembrane pore for the release of Cyt c from mitochondria. 
Notably, upon translocation at mitochondria, p53 has been shown to play a role in 
maintaining mitochondrial genetic stability. Indeed, in response to mitochondrial damage p53 
interacts with Polγ and enhances its DNA replication functions (Achanta, Sasaki et al. 2005) . 
Moreover it has been proposed that p53 might interact with mtDNA (Heyne, Mannebach et al. 
2004) and that it might participate in mitochondrial base excision repair (mtBER) (de Souza-
Pinto, Harris et al. 2004). 
The precise contribution of the transcriptional-independent apoptotic activities of p53 to the 
overall apoptotic response needs to be figured out much more in detail. However, they seem 
to be important, as demonstrated by the fact that the stronger capacity of the isoform 
p53Arg72 to activate apoptosis as compared to the Pro72 form, is associated at least in part 
with the greater ability of Arg72 isoform to localize to mitochondria (Dumont, Leu et al. 
2003). 
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Recent reports showed that p53 can also modulate autophagy, a cellular process triggered by 
nutrient starvation and genotoxic agents that may function in different contexts to either 
promote or inhibit cell survival (Crighton, Wilkinson et al. 2006; Crighton, Wilkinson et al. 
2007). DRAM (damage-regulated autophagy modulator), a p53-induced protein, has been 
identified to be a likely linker between p53-dependent apoptosis and autophagy. In fact p53 
induces autophagy in a DRAM-dependent manner and DRAM, which has been found to be 
down regulated in human cancer, has proven to be also critical for p53-induced cell death. 
Nevertheless, other works suggested that p53 downregulation induces autophagy in different 
cell types and that cytoplasmic p53 inhibits autophagy in p53 knockdown cells (Tasdemir, 
Maiuri et al. 2008). 
 
c.3) Senescence 
 
Cellular senescence is a program leading to an irreversible cell cycle arrest that is 
accompanied by a characteristic set of phenotypic changes in the cell. Senescence was first 
observed as the limited ability of normal cells to grow in culture; after several cycles of cell 
division, proliferation declines and cells enters in a permanent arrested state (Hayflick 1965). 
Since this process seems to be regulated by several tumor suppressors and oncogenes in 
normal cells and mechanisms that bypass senescence appear to be important in cancer 
development, senescence was proposed as a tumor suppressive mechanism (Campisi 2001; 
Wright and Shay 2001; Dimri 2005; Braig and Schmitt 2006). Senescence response is elicited 
by DNA damage and oncogenic and mitogenic signals, so in this scenario senescence acts as a 
failsafe mechanism.  
Senescent cells acquire some characteristic features or senescent phenotype. When normal 
cells are exposed to potentially oncogenic insults, they irreversibly cease to proliferate 
(growth arrest), and often become resistant to apoptosis (apoptosis resistance) (Chen, Liu et 
al. 2000; Hampel, Malisan et al. 2004; Marcotte, Lacelle et al. 2004; Murata, Wakoh et al. 
2006), and show changes in gene expression (altered gene expression) (Zhang, Pan et al. 
2003; Yoon, Kim et al. 2004; Trougakos, Saridaki et al. 2006), including changes in known 
cell-cycle inhibitors and activators, like induction of p21 and p16 or repression of c-Fos, 
cyclin A, cyclin B and PCNA. Moreover, senescent cells can be identified in culture by 
morphological means like large cell size, flat vacuolated morphology or by several distinctive 
markers, like the incorporation of 5-bromodeoxyuridine or 3H-thymidine, or the 
immunostaining for proteins such as PCNA and Ki-67, to detect the lack of DNA replication. 
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One of the first and classical marker of senescence, is the senescence-associated β-
galactosidase (SA-βgal) that derives from the lysosomal β-galactosidase and reflects the 
increased lysosomal biogenesis that commonly occurs in senescent cells (Dimri, Lee et al. 
1995; Lee, Han et al. 2006). More recently, other senescence markers have been identified, 
such as the expression of p16, an important regulator of senescence (Krishnamurthy, Torrice 
et al. 2004), and the detection of cytological markers like senescence-associated 
heterochromatin foci (SAHFs) (Narita, Nunez et al. 2003) and senescence-associated DNA-
damage foci (SDFs) (d'Adda di Fagagna, Reaper et al. 2003; Takai, Smogorzewska et al. 
2003; Herbig, Jobling et al. 2004; Di Micco, Fumagalli et al. 2006). SAHFs which silence the 
genes that are needed for proliferation are detected by preferential binding of DNA dyes and 
the presence of certain heterochromatin-associated histone modifications (for example, H3 
lys9 methylation) and proteins (for example, heterchromatin protein-1 (HP1)). SDFs contain 
proteins that are associated with DNA damage, and can be visualized by staining of such 
proteins, for example phosphorylated histone H2AX (γ-H2AX) and p53-binding protein-1 
(53BP1).  
Senescence can be triggered by different stimuli, like the shortening of telomeres due to 
proliferation (replicative senescence) (Harley, Futcher et al. 1990; Herbig, Jobling et al. 
2004) or by other exogenous or endogenous acute and chronic stress signals (telomere-
independent or premature senescence) such as cytokine signalling (TGFβ) oxidative 
damage (Di Leonardo, Linke et al. 1994; Chen, Liu et al. 2000), or by mitogenic oncogene 
overexpression (Ras, Raf) (Serrano, Lin et al. 1997; Zhu, Woods et al. 1998; Ferbeyre, de 
Stanchina et al. 2000; Michaloglou, Vredeveld et al. 2005), loss of anti-oncogenic tumor 
suppressors (PTEN) (Chen, Trotman et al. 2005) or supra-physiological mitogenic signals 
(overexpressed MAPK or E2F1) (Lin, Barradas et al. 1998; Dimri, Itahana et al. 2000) 
(oncogene-induced senescence). In both replicative, premature or oncogene-induced 
senescence, a key role is mediated by tumor suppressor pathways involving p53 and p16INK4a-
pRB (Shay, Pereira-Smith et al. 1991; Serrano, Lin et al. 1997) as demonstrated by a general 
refractoriness of human cells to multiple senescence-inducing stimuli upon loss of p53 and 
pRB function (Dimri, Itahana et al. 2000; Beausejour, Krtolica et al. 2003). These two 
pathways interact but can also independently halt cell-cycle progression and to some extent 
they respond to different stimuli in a cell-type or species-specific fashion. Most studies 
suggest that p21 induction by p53 inhibits CDK2/Cyclin E activity. Activity of CDK4/Cyclin 
Ds can also be inhibited by p21. Inhibition of activity of CDKs by p21 results in 
hypophosphorylation of pRB, which very likely mediates arrest during senescence (Itahana, 
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Campisi et al. 2004). In contrast to p53, the role of pRB in cellular senescence is less clear. 
pRB remains constitutively hypophosphorylated in senescent cells (Stein, Drullinger et al. 
1999), suggesting downregulation of the activity of pRB kinases during senescence. The 
p16INK4a, an inhibitor of CDK4 and CDK6 activity, is upregulated during senescence (Alcorta, 
Xiong et al. 1996; Stein, Drullinger et al. 1999), accounting for the hypophosphorylation of 
pRB. Nevertheless, it was reported that downregulation of p16 may not be functionally 
equivalent to pRB inactivation (Wei, Herbig et al. 2003), leaving the possibility that other 
CDKs inhibitors might play a surrogate role in cellular senescence. Since p21 induction can 
also lead to the inhibition of pRB phosphorylation by inhibiting CDK2/Cyclin E activity, p16 
and p21 are likely to cooperate to keep pRB in a hypophosphorylated form during senescence. 
Alternatively, it is possible that p21 initially and temporarily keeps pRB in its inhibitory form, 
while p16 ensures permanent hypophosphorylation of pRB (Beausejour, Krtolica et al. 2003). 
The p16-pRB pathway is crucial for generating SAHFs (Narita, Nunez et al. 2003). SAHFs 
contains chromatin modifiers proteins like HIRA (histone repressor A), ASF1a (anti-silencing 
function-1a) and HP1, and finally after formation they are composed of a single condensed 
chromosome, which is depleted for the linker histone H1 and enriched for HP1 and histone 
variant macroH2A (Zhang, Poustovoitov et al. 2005; Zhang, Chen et al. 2007). Like the 
growth arrest, once established, SAHFs no longer require p16 or pRB for maintenaice. This 
suggest that the p16-pRB pathway can establish self-maintaining senescence-associated 
heterochromatin (Campisi and d'Adda di Fagagna 2007). 
Recent work has revealed the importance of DNA-damage response (DDR) in initiating and 
maintaining cellular senescence (d'Adda di Fagagna 2008). DDR is a pathway that senses 
DNA damage and triggers an amplified cascade of events that coordinates cell cycle arrest 
with DNA repair (Fig. K) (Nyberg, Michelson et al. 2002). DDR is activated in response to 
generation of single-stranded DNA and/or DNA double strand breaks (DSBs), that are sensed 
by large protein complexes that recruit and activate ataxia telangiectasia and Rad3-related 
(ATR) or ataxia-telangiectasia mutated (ATM), respectively, at the site of the DNA lesion. 
These kinases then phosphorylate the histone H2AX, leading to further recruitment of ATM 
complexes in a positive feedback loop, thus engaging a signal cascade mediated by different 
DNA-damage mediators (for example, MDC1, 53BP1 and TOPBP1) and other downstream 
kinases, like CHK1 and CHK2. These two kinases finally activate the effectors of the DDR 
signalling, p53 and CDC25. Dysfunctional telomeres trigger a classical DDR, the progressive 
telomere shortening eventually cause chromosome ends to be recognized as DNA breaks, 
consequently activating the ATM-p53-p21 branch of DDR and enforcing senescence (d'Adda 
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di Fagagna, Reaper et al. 2003; Herbig, Jobling et al. 2004). Stimuli that produce a DDR can 
also engage the p16-pRB pathway, but this usually occurs secondary to engagement of the 
p53 pathway (Stein, Drullinger et al. 1999; Jacobs and de Lange 2004; Jacobs and de Lange 
2005). A common signal in oncogene-induced senescence is the occurrence of double strand 
breaks caused by oncogene activation through aberrant DNA replication. Inactivation of key 
DDR gene products leads to senescence avoidance and cell proliferation and allows cell 
transformation (Bartkova, Rezaei et al. 2006; Di Micco, Fumagalli et al. 2006; Hemann and 
Narita 2007; Mallette, Gaumont-Leclerc et al. 2007).  
 
 
Fig. K: The DNA damage response (DDR) pathway
d’Adda di Fagagna F., Nat Rev Cancer, 2008
 
 
 
As previously described, p53 is positively and negatively regulated by a multitude of factors. 
The E3 ubiquitin ligases MDM2, PIRH2, and COP1 negatively regulates p53 by targeting it 
for proteosome-mediated degradation (Lu 2005). On the other hand, p53 is positively 
regulated by ARF, PML, PTEN, NPM, p33ING1, and other tumor suppressors, which 
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posttranslationally stabilize p53 (Weber, Taylor et al. 1999; Leung, Po et al. 2002; Freeman, 
Li et al. 2003; Bernardi, Scaglioni et al. 2004; Kurki, Peltonen et al. 2004). All these p53 
regulators can also impact cellular senescence (Dimri 2005). 
Among p53 regulators, promyelocytic leukemia protein (PML) has shown to be an important 
mediator of senescence. PML nuclear bodies (PML-NBs) are distinct nuclear structures that 
have multiple cellular functions (see later) and whose number increase during senescence. 
Actually, it was demonstrated that RAS-induced senescence is associated with increased PML 
levels leading to an increase in the size and the number of PML-NBs, high p16 levels, pRB 
hypophosphorylation, p53 phosphorylation at serine 15 and activation of p53 transcriptional 
targets (Ferbeyre, de Stanchina et al. 2000). Moreover, p53 is acetylated at lysine 382 upon 
RAS expression, and RAS induces relocalization of p53 and CBP acetyltransferase within the 
PML-NBs, favouring the formation of a trimeric p53-PML-CBP complex (Pearson, Carbone 
et al. 2000). Furthermore, the NAD-dependent histone deacetylase SIRT1, is recruited to 
PML-NBs upon overexpression of either PML or oncogenic RAS, inducing p53 
deacetylation, and inhibiting PML- and p53-induced premature senescence (Langley, Pearson 
et al. 2002). More detailed studies have recently suggested that PML isoform IV (PML3), 
when overexpressed induces senescence in human fibroblast in a p53- and pRB- dependent 
manner (Bischof, Kirsh et al. 2002; Mallette, Goumard et al. 2004; Bischof, Nacerddine et al. 
2005). Recently, PML-NBs have been shown to regulate another important aspect of cellular 
senescence: the formation of SAHFs. The chromatin remodelling process that occur during 
SAHFs formation is mediated by PML-NBs because, before localization to SAHFs, the 
histone chaperone HIRA translocates to PML-NBs. HIRA localization to PML-NBs is indeed 
one of the first steps in the senescence programme because it precedes all other markers of 
senescence and is a necessary event for the formation of SAHFs and the progression of 
senescence (Zhang, Poustovoitov et al. 2005; Ye, Zerlanko et al. 2007). 
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3. Aim of the thesis 
 
Due to their high degree of sequence homology, MAGE-I proteins were considered for a long 
time as functionally redundant proteins. Nevertheless, in the last few years emerging data 
suggested that MAGE-I proteins could display specific functions possibly related to cell 
transformation. However, there is still little information about the potential and specific roles 
that individual MAGE-I proteins could play in these processes.  
In this Thesis, we aimed to functionally characterize different MAGE-I genes, in particular 
MageA2 and MageB2 genes, in order to demonstrate their functional specificity, despite their 
sequence homology. The major starting readout to dissect the respective roles of  the analyzed 
MAGE-I proteins was the p53 tumor suppression pathway.  
The general framework aim was in fact to reconsider the specific cellular functions and the 
respective pathways that are targeted by the different family members to generate critical 
knowledge for exploiting MAGE-I genes as targets to be specifically inactivated in cancer 
cells. 
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4. Results 
 
Part I: MAGE-A tumor antigens target p53 transactivation function through histone 
deacetylase recruitment and confer resistance to chemotherapeutic agents 
 
MAGE-A proteins repress p53 function with different efficiency 
 
At the beginning of this study, experiments carried out in collaboration with Dr. Monica 
Rodolfo (Istituto Nazionale Tumori, Milano, Italy) showed a strong correlation between 
MAGE-A proteins levels, in particular MageA2, A6 and A12, and resistance to 
chemotherapeutic drugs such as cisplatin (CP) and etoposide (ET) in primary melanoma cells 
harboring wild type p53 (Fig. 1A and 1B). 
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Fig. 1: MAGE-A correlates with resistance to chemotherapeutic drugs in tumors harboring wild type p53
Melanoma cell lines expressing No or Low MAGE-A levels (M1, M2 and M3) (A) and those expressing High MAGE-A 
levels (M4, M5 and M6) (B) were treated with different doses of ET or CP as indicated. Cell viability was calculated
by MTT assay 72 hours after treatment. 
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Consequently, we asked whether MAGE-A proteins could have an effect on p53 function. We 
observed that MAGE-A proteins such as MageA1, A2 and A6 were able to repress p53 
transactivation function in gene reporter assays using a vector containing p53 responsive 
sequences as synthetic promoter for the luciferase gene (pG13-Luc) (Fig. 2A). The assay 
indicated that MageA2 exerts the strongest repressive effect on p53 as compared with other 
MAGE-A proteins. For this reason, we decided to use MageA2 in the following studies. A 
similar analysis was performed using a panel of p53 responsive promoters, confirming the 
efficiency of MageA2 in down-regulating p53 activity (Fig. 2B). Expression of MageA2 did 
not alter p53 protein levels, as evaluated on the same lysates used for gene reporter assay (Fig. 
2C).  
 
 
A B
p53
HA-MageA2
p53
HA-MageA2
+ + + + + + + +
+ + + +
-
- - - - -
Rep-LUC Mdm2pG13 Bax p21
Actin
C
H1299 cells
H1299 cells
0
20
40
60
80
100
120
empty
vector
p53 p53 +
MageA1
p53 +
MageA2
p53 +
MageA6
R
el
at
iv
e 
LU
C
 a
ct
iv
ity
0
20
40
60
80
100
120
pG13LUC Mdm2LUC BaxLUC p21LUC
R
el
at
iv
e 
LU
C
 a
ct
iv
ity
empty vector MageA2 p53 p53 + MageA2
Fig. 2: MageA2 expression represses p53 transactivation function
A) p53-specific reporter gene assay performed in H1299 cells (p53 null) transfected with p53, or in combination
with MageA1, MageA2 and MageA6 together with the p53-responsive promoter pG13LUC. Value 
corresponding to p53 transfection was reported to 100. B) p53-specific reporter gene assay as performed in “A”
using p53 and MageA2 together with different p53-responsive promoters. C) The levels of transfected p53 and
HA-MageA2 from lysates used in “B” were analyzed by western blot using DO-I and anti HA tag antibodies,
respectively. Actin levels were used as loading control.
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We then determined the effect of MageA2 expression on the endogenous levels of p53 target 
genes. We established the HA-MageA2 inducible U2OS cell line (named M20 cells) under 
the control of Ponasterone A (PonA). Although p53 protein levels were comparable in cells 
overexpressing or not HA-MageA2 upon treatment with ET, the endogenous levels of p53 
targets, p21Waf-1 and Bax, were markedly reduced in cells expressing HA-MageA2 (Fig. 
3A). Conversely, siRNA mediated knockdown of MageA2 in U2OS cells resulted in an 
earlier accumulation of p53 targets after DNA damage (Fig. 3B). 
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Fig.3: MageA2 expression represses p53 targets expression without affecting p53 levels
A) Western blot analysis of M20 cells (HA-MageA2 inducible U2OS cells) expressing (+PonA) or not (No PonA) HA-MageA2.
p53, bax and p21 protein levels were determined at the indicated time-points after treatment with 10 uM ET. B) Determination
of p53, bax and p21 protein levels after ET treatment in U2OS cells transfected with control siRNA (siCont) or Mage siRNA
(siMage).  
 
 
We then analyzed the effect of MageA2 on p53 biological functions, using DNA damage-
induced growth arrest and apoptosis as readouts. Overexpression of MageA2 resulted in 
impaired DNA damage induced growth arrest as assessed by BrdU incorporation in M20 cells 
upon treatment with ET (Fig. 4A). Moreover, MageA2 expression correlated with resistance 
to ET treatment as evaluated in M20 cells overexpressing MageA2 (Fig. 4B) and in U2OS 
cells transfected with specific siRNA for knocking down MAGE-A levels (Fig. 4C). No 
significant protection to ET treatment was seen in p53-null Saos-2 cells by MageA2 
expression, which, however, efficiently inhibited cell death induced by p53 overexpression 
(Fig. 4D). These data support the notion that after DNA damage the p53 dependent response 
is impaired in cells overexpressing MageA2. 
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Fig. 4: MageA2 expression impairs p53 dependent damage-induced growth arrest and apoptosis
A) Growth arrest was determined by BrdU incorporation in M20 cells expressing (PonA+) or not (no PonA) 
HA-MageA2 after treatment with 10 uM ET for 16 hs. 200 cells were counted for at least 3 independent experiments.
B) Apoptosis determination by Annexin V assay coupled to FACS analysis (10.000 counted cells for at least
3 independent experiments). M20 cells were treated with 20 uM ET for 36 hours. C) Similar experiment as shown in 
“B”, but performed in U2OS cells previously silenced using siRNA as indicated. D) Apoptotic scoring in p53-null
Saos-2 cells expressing or not HA-MageA2 treated with 20 uM ET for 36 hours (see ET) or overexpressing p53 for 
48 hours (see p53). Apoptosis was determined by nuclear morphology on transfected cells using Hoechst dye. 200 cells
were counted for at least 3 independent experiments.
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MageA2 can physically interact with p53  
 
In order to evaluate a potential interaction between Mage-A and p53 proteins, we performed 
immunoprecipitation assays in U2OS cells, which revealed an association between 
endogenous p53 and MAGE-A proteins (Fig. 5A). A set of p53 deletion mutants were used to 
map the interaction between MageA2 and p53, demonstrating that the complex formation in 
vivo required the p53-DNA-binding domain (p53DBD, amino acids 94-298), whereas the p53 
transactivation domain (amino acids 1-98) and the p53-C-terminal domain (p53CTD, amino 
acids 298-393) were dispensable (Fig. 5B and 5C). We also performed in vitro pull-down 
experiments showing that recombinant GST-p53 associated with in vitro translated (IVT) 35S-
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labeled MageA2 (Fig. 5D) and that GST-MageA2 bound specifically to the p53DBD but not 
to p53CTD or the N-terminal domain (p53NTD, amino acids 1-98) (Fig. 5E), suggesting a 
direct interaction between these proteins. 
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Fig. 5: Interaction between MageA2 and p53
A) Immunoprecipitation of endogenous p53/Mage protein complex in U2OS cells using anti-p53 polyclonal 
antibody or preimmune IgG. Western blot were performed by using p53 (DO1) and Mage (57B) antibodies. 
B) Immunoprecipitation in H1299 cells transfected with HA-MageA2 and p53 deletion mutants (p53 (1-98) 
and p53 (1-298)) using polyclonal anti-p53 antibody. DO1 (p53) and anti-HA were used in the Western blot. 
C) Immunoprecipitation assay similar to that in “B” but using p53 deletions expressing HA-p53 94-298
(HA-p53DBD) and HA-p53 298-393 (HA-p53CTD). MageA2 was used as His-tagged version. D) In vitro
binding assay using recombinant/purified GST and GST-p53 fusion protein incubated with in vitro translated
35S-labeled HA-MageA2 (IVT MageA2). E) In vitro binding assay using recombinant/purified GST and
GST-MageA2 fusion protein incubated with IVT 35S-labeled domains of p53: p53NTD (1-98), p53DBD
(94-298), and p53CTD (298-393) as indicated. * indicates immunoglobulin heavy chain, ** indicates
immunoglobulin light chain.  
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MageA2 impairs p53 acetylation by assembling HDAC3/p53 complex 
 
p53 function has been shown to be tightly regulated by many different mechanisms that 
include specific post-translational modifications, as phosphorylation, acetylation, 
ubiquitylation, neddylation, methylation and sumoylation (Bode and Dong 2004; Murray-
Zmijewski, Slee et al. 2008). We analyzed the profile of p53 modifications, in particular 
phosphorylation and acetylation, in M20 cells after treatment with DNA damaging agents. ET 
treatment caused rapid p53 phosphorylation on Ser-15, independently of MageA2 induction, 
whereas acetylation of Lys-382 was severely impaired in MageA2 overexpressing M20 cells 
(Fig. 6A). Moreover, the use of HDAC inhibitor Trichostatin A (TSA) counteracted the effect 
of MageA2 expression on p53 acetylation (Fig. 6B), suggesting that a balance between 
histone acetyl-transferases (HATs)/HDACs activities could be affected in cells 
overexpressing MageA2. 
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Fig. 6: MageA2 induces p53 deacetylation
A) Time-course experiment in M20 cells after addition of 10uM ET. PonA was added 
15 hours before ET treatment. DO1 antibody was used for total p53, while anti-P-p53Ser15
(P-p53) and anti-Ac-p53Lys382 (Ac-p53) were used for specific phosphorylation and
acetylation. HA-MageA2 expression was determined using anti-HA antibody. 
B) Similar to “A” but using 300 nM TSA together with ET treatment on M20 cells 
expressing or not HA-MageA2.  
 
Since it was previously reported that MageA1 can bind to HDAC1 (Laduron, Deplus et al. 
2004), we decided to investigate whether MageA2 could associate with HDACs as a potential 
mechanism to control p53 activity. Induction of MageA2 in M20 cells and knocking-down of 
MAGE-A in U2OS cells, correlated with similar changes in HDAC3 protein levels with 
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respect to HDAC1 (Fig. 7A). Therefore, we focused our studies on the relationship between 
MageA2 and HDAC3. HA-MageA2 was immunoprecipitated from transiently transfected 
293T cells where endogenous HDAC3 was found to form a complex with MageA2. As 
expected, endogenous p53 coimmunoprecipitated with MageA2 (Fig. 7B). By in vitro pull-
down experiments we detected a weak but reproducible interaction between recombinant 
GST-MageA2 and IVT 35S-labeled HDAC3 (Fig. 7C). The possibility that MageA2 could 
recruit HDACs to p53 was confirmed by the finding that Flag-HDAC3/endogenous p53 
association was stronger in the presence of MageA2 (Fig. 7D).  
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Fig. 7: MageA2 recruits HDAC3 to p53
A) Endogenous levels of HDAC1 and HDAC3 were assessed by western blot in M20 cells 24 and 48 hs after the 
induction of HA-MageA2 (PonA) (left panel), and in U2OS cells transfected for 30 and 72 hs with control siRNA
(siC) or Mage siRNA (siM) (right panel), using anti-HDAC1 and anti-HDAC3 polyclonal antibodies. HA-Mage and
Mage were detected using anti-HA and anti-MageA monoclonal antibodies, respectively. B) Immunoprecipitation
of transiently transfected 293T cells with HA-MageA2 using anti-HA antibody. Anti-p53 and anti-HDAC3 polyclonal
antibodies and anti-HA were used for Western blot as indicated. C) In vitro binding assay using recombinant/purified
GST and GST-MageA2 fusion protein incubated with in vitro translated 35S-labeled HDAC3. D) Immunoprecipitation
of transiently transfected 293T cells with HA-MageA2 and Flag-HDAC3 expression vectors using anti-Flag antibody
as indicated. Endogenous p53 was detected using anti-p53 polyclonal antibody.  
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MageA2/HDAC3 complex can associate with p53 on its DNA-binding sites  
 
To evaluate whether the MageA2/HDAC3/p53 complex could associate to a p53 responsive 
promoter, Chromatin Immunoprecipitation (ChIP) assay was performed after cotransfection 
of p53, MageA2 and HDAC3 in p53 null H1299 cells. Briefly, cells were transfected with 
pBax-Luc, p53 and Flag-MageA2 or Flag-HDAC3 as indicated in Figure 8B. Samples were 
immunoprecipitated with an anti-Flag antibody, followed by pBax-Luc PCR amplification 
using the Fw primer on the Bax promoter and the Rev primer on the Luc gene (Fig. 8A). We 
observed that MageA2 was able to bind the Bax promoter only when p53 was transfected, and 
that HDAC3 required p53/MageA2 complex to associate with this promoter (Fig. 8B). 
To assess whether HDAC3 in complex with MageA2 conserved its deacetylating activity, we 
transfected H1299 cells with HA-MageA2 and Flag-HDAC3 and used the immuno-complex 
in an in vitro deacetylase assay by using 14C-acetylated histones as substrate for the reaction. 
Autoradiography revealed strong in vitro deacetylase activity of the complex (Fig. 8C), 
indicating that MageA2 could assemble active HDAC3 to p53 complex as part of its 
repressive function. 
 
 
HDAC3/MageA2/p53 complex induces histone hypoacetylation at p53-binding sites 
 
Overexpression of MAGE-A genes was originally found in melanoma, a human tumor highly 
refractory to chemotherapy even though harboring wt-p53 (Albino, Vidal et al. 1994; 
Satyamoorthy, Chehab et al. 2000). Therefore, we analyzed the p53-dependent response in 
two human short-term cell lines obtained from melanoma biopsies expressing different 
MAGE-A levels and harboring wt-p53 (15392M and 13923M) (van Baren, Brasseur et al. 
1999; Daniotti, Oggionni et al. 2004). 15392M cells express very low levels of MAGE-A 
while 13923M cells express high levels of MAGE-A. Upon ET treatment, the p53 response as 
well as p53 acetylation were severely impaired in 13923M cells expressing high MAGE-A 
levels when compared to 15392M cells expressing low MAGE-A levels (Fig. 9A and 9B). 
Importantly, both acetylation as well the p53 response to ET were restored, as determined 
both by p53 acetylation and p21 and bax protein levels, when TSA was used in combination 
with ET (Fig. 9C).  
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Fig. 8: Active MageA2/HDAC3 complex is recruited to p53 binding sites on chromatin
A) Diagram showing the PCR amplification approach of pBax-Luc DNA used for ChIP assay. B) Upper panel: ChIP
performed in H1299 cells transfected with pBax-Luc, p53 and Flag-tagged construct as indicated. Samples were
immunoprecipitated (ChIP) or not (input) using anti-Flag antibody, followed by pBax-Luc PCR amplification using a 
Fw primer recognizing the 5’ of the transfected Bax promoter and a Rev primer recognizing the Luc gene (see diagram
in “A”). Lower panel: control of the indicated transfections by western blot. C) Upper panel: Immunoprecipitation
of transiently transfected H1299 cells with HA-MageA2 and Flag-HDAC3 using anti-HA antibody. Lane 1 and 2 show
the absence and presence of MageA2/HDAC3 complex, respectively. Lower panel: In vitro deacetylation assay of
14C-acetylated histones (Ac-Hist) by immunoprecipitated complex shown in Lane 1 (IP-1) and Lane 2 (IP-2) of the 
upper panel. Input indicates mock-treated 14C-acetylated histones. MW is 14C-labeled protein molecular weight. 
# indicates unspecific band. * indicates immunoglobulin heavy chain.  
 
 
 
 
                                                                                                                                         Results I 
 - 59 -
B C
Hours ET: 0 6 12 0 6 12
Mage
15392M 13923M
melanoma cells
Ac-p53
p53
P-p53
actin
Hours ET: 0 6 12 0 6 12
Mage
p53
p21
bax
actin
15392M 13923M
melanoma cells
A
melanoma cells
Mage
Ac-p53
p53
actin
Hours ET: 0 12 0 12
15392M 13923M
+TSA
p21
bax
Fig. 9: MAGE-A deacetylates and inhibits p53 in melanoma cells
A) DNA-damage response in melanoma cells expressing low (15392M cells) or high (13923M) 
MAGE-A levels, after treatment with 20uM ET. MAGE-A, p53, bax and p21 protein levels were
determined at the indicated time-points. B) Analysis of p53 modification in 15392M and 13923M
melanoma cells after ET damage (20uM). p53 modifications were determined using anti-P-p53Ser15
(P-p53) and anti-Ac-p53Lys382 (Ac-p53). C) Similar to “B” but using 300 nM TSA together with
ET (20uM) treatment in 15392M and 13923M melanoma cells.  
 
 
We then asked whether deacetylation of histones surrounding p53 binding sites on promoter 
DNA could be an additional target for HDAC recruited by MageA2 to exert p53-dependent 
transcription repression. p53/MageA2/HDAC3 protein complex can be found assembled at 
p53 binding sites (Fig. 8B), suggesting that the inhibitory effect of such complex could be 
extended to other acetylation-dependent substrates critically involved in transcription 
regulation such as nucleosome histones. In fact, MageA2 was able to down-regulate the 
transcriptional activity of the non-acetylable p53 mutant, p539KR (Ard, Chatterjee et al. 
2002) both alone or when cotransfected with the histone acetyl-transferase p300 (Fig. 10A 
and 10B), strongly suggesting that histone hypoacetylation could represent the main 
mechanism used by MageA2 for targeting p53 activity. 
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Fig. 10: MageA2 repress the transcriptional activity of non-acetylable p53
A) Analysis of MageA2 function on wt-p53 transcription activity with or without the addition of p300. H1299 cells
(p53 null) were transiently transfected with expression vectors encoding p53, HA-MageA2 and HA-p300 combined 
as indicated, together with BAX promoter containing the fire-fly luciferase gene (pBax-Luc) as reporter. MageA2 was 
transfected in two different amounts: 100ng (Mage 0.1) or 300ng (Mage 0.3). LUC activity was assessed 24 hours later. 
pCMV-renilla luciferase vector was cotransfected to normalize transfection efficiency. B) Analysis of MageA2 function
on mutated p53 (p539KR) transcription activity with or without the addition of p300 as performed in “A”.
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Using 15392M and 13923M melanoma cells as model, we analyzed both endogenous 
protein/chromatin complexes as well as chromatin acetylation status using a quantitative ChIP 
approach (ChIP followed by real time PCR) before and after DNA-damage. As shown in Fig. 
11A,  p53 was similarly recruited to p21 or Bax promoter after ET treatment independently of 
MAGE levels, as evidenced by the ratio between damaged/undamaged ChIP value, thus 
confirming that MAGE-A expression does not affect the DNA binding ability of p53. 
However, significant HDAC3 recruitment to p21 and Bax promoters after damage was clearly 
related to MAGE-A expression. On the contrary, histone H3 acetylation level increased more 
efficiently after damage in cells lacking MAGE-A when compared to cells expressing high 
MAGE-A levels. Addition of TSA caused a global histone acetylation status in both cell 
strains resulting in no difference (ratio next to 1) with respect to ET addition. Similar data was 
obtained when the MageA2-inducible M20 cell line was tested (Fig. 11B). Altogether our data 
support the notion that MAGE-A proteins could recruit HDACs to p53 causing 
hypoacetylation of histones surrounding p53 binding sites and of p53 protein itself, thus 
weakening the p53-dependent transactivation function. 
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Fig. 11: MageA2/HDAC complex deacetylates p53 and histones surrounding p53-binding sites
A) ChIP assay followed by quantitative PCR analysis using real-time PCR. Protein/DNA complexes were 
immunoprecipitated from 15392M and 13923M melanoma cells before and after ET treatment using the antibodies 
indicated in the X axis. AcH3 is acetylated histone H3 antibody. TSA indicates TSA treatment. Data are expressed as
the ratio between damaged/undamaged ChIP values, therefore indicating the enrichment of each protein to the indicated
promoter after damage. B) ChIP assay followed by quantitative PCR analysis using real- time PCR as in “A”. Protein/DNA
complexes were immunoprecipitated from non induced (white) or PonA induced (black) HA-MageA2 expression in M20
cells before and after ET treatment. The antibodies are indicated in the X axis, MageA2 was immunoprecipitated using the
HA anti-tag monoclonal antibody. 
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Melanoma cells expressing MAGE-A genes are refractory to DNA damage-induced 
apoptosis 
 
By using melanoma cells as model, we evaluated the correlation between MAGE-A 
expression and resistance to apoptosis. ET treatment of 15392M and 13923M melanoma cells 
showed a dose-dependent induction of cell death in cell expressing low MAGE-A levels, 
while cells expressing high MAGE-A levels remained almost insensitive to such treatment 
(Fig. 12A). Importantly, addition of TSA (able to efficiently stimulate p53 function in cell 
expressing high levels of MAGE-A, see Fig. 9C) significantly sensitized 13923M cells to ET 
induced apoptosis (Fig. 12A). Similar effects were observed in MageA2-inducible M20 cell 
line (Fig. 12B). Melanoma cell lines harboring mutant p53 were found to be strongly resistant 
to ET/TSA treatment independently of MAGE-A expression as assessed in SK-Mel-28 (high 
MAGE-A expression) and BE cells (low MAGE-A expression) (Fig. 12C), supporting the 
hypothesis that MAGE-A proteins could exert their function by suppressing wt-p53 function.   
The direct relevance of MAGE-A levels and wt-p53 activity in resistance to DNA-damaging 
agents was then analyzed in 13923M cells. MAGE-A levels were down-regulated by pSuper-
Retro (pSR) retrovirus vector transducing siRNA designed for targeting a highly conserved 
sequence of several MAGE-A genes (pSRMage). p53 activity was controlled by using pBabe-
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EGFP-TNVp53OD (Gostissa, Morelli et al. 2004) retroviral vector (p53OD) encoding a p53 
oligomerization domain peptide (amino acids 322-355) able to repress p53 function. 13923M 
cells were co-infected with pSR or pSRMage (Puromycin resistance) and pBabe or 
pBabep53OD (Hygromycin resistance) as indicated. Puromycin/Hygromycin resistant cells 
were selected to perform the experiment. Significant increase in susceptibility to ET was 
observed in 13923M-pSRMage cells when compared to their control, 13923M-pSR cells. This 
effect was clearly reduced when p53 activity was inactivated through p53OD (Fig. 12D), 
indicating that down-regulation of MAGE-A genes triggers p53-dependent cell death in cells 
treated with ET.  
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Fig. 12: MAGE-A expression correlates with resistance to DNA damage-induced apoptosis
A) Apoptosis determination by subG1 by FACS analysis (10.000 counted cells for at least 3 independent experiments) in 
15392M and 13923M cells. Melanoma cells were treated with the indicated concentration of ET for 48hs. Where indicated, 
300nM TSA was added together with ET. B) Similar to “A” but using M20 cells expressing (+PonA) or not (No PonA) 
HA-MageA2 and treated with 40uM ET for 36hs. C) Similar to “A” but using melanoma cell lines harboring mutant p53.
D) Left panel: Apoptosis determination by subG1/FACS analysis in 13923M cells co-transduced with siRNA vector, pSR
(empty) or pSRM (for Mage knock-down) and pBABE (empty) or pBABE.GFP-p53OD (for p53 inactivation) as indicated.
Cells were treated with 40uM ET for the indicated time. Right panel: determination of MAGE-A protein levels and the 
expression of GFP-p53OD in 13923M-pSR and 13923M-pSRM cells using anti-MAGE and anti-GFP polyclonal antibodies,
respectively. 
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In summary, in this part of the work we demonstrated that MageA2 protein confers resistance 
to chemotherapeutic drugs such as ET, by recruitment of HDAC3 to p53, thus repressing p53 
transactivation function. The mechanism responsible for the repressive effect of MageA2, 
relies on an impaired acetylation of both p53 and histones surrounding p53 binding sites by 
MageA2/HDAC3 complexes (Fig. 13). Finally, the correlation between MAGE-A expression 
and resistance to apoptosis has been validated in short-term melanoma cell lines, where 
combined treatment with ET and TSA restores de p53 response and reverts chemoresistance 
of melanoma cells expressing high levels of MAGE-A.  
 
 
Fig. 13: Proposed model for the repressive effect of MageA2 on p53 function
Upon DNA damage, p53 becomes acetylated and activates the transcription of its targets genes (left); the 
formation of MageA2/HDAC3 complexes leads to the deacetylation of p53 and histones surrounding p53
binding sites, leading to transcriptional repression (right). Ac: acetyl groups. K: lysine residue.  
 
 
 
Most of the data and results described in this Part I have been published in: 
“MAGE-A tumor antigens target p53 transactivation function through histone deacetylase 
recruitment and confer resistance to chemotherapeutic agents”. Monte M, Simonatto M*, 
Peche LY*, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M, Schneider C. Proceedings of the 
National Academy of Sciences of the United States of America; 130:11160-11165; 2006. 
* Simonatto M and Peche LY equally contributed in this work    
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Part II: MageA2 regulates PML3-induced p53 activity 
 
MageA2 impairs PML3 induced senescence 
 
Loss of senescence is an early step during cell transformation. Here we have analyzed the 
potential role of MageA2 in interfering the PML3-p53 axis and its consequence on cellular 
senescence. Acetylation is a relevant modification for p53 activity, and several stimuli such as 
DNA damage are responsible for the induction of p53 acetylation (Bode and Dong 2004). 
Most specifically, p53 acetylation has also been associated with the promyelocytic leukemia 
(PML) tumor suppressor protein. In particular, it has been demonstrated that PML3 activates 
p53 (Fogal, Gostissa et al. 2000) inducing the recruitment of p53 to the PML-Nuclear Bodies 
(PML-NBs) where p53 becomes acetylated, leading to enhanced p53 activity for induction of 
premature senescence (Ferbeyre, de Stanchina et al. 2000; Pearson, Carbone et al. 2000).  
Normal human fibroblast (Wi38 cells) were co-infected with PML3, and control or MageA2 
expressing retroviruses. It has been reported that in this cellular system the prolonged 
expression of PML3 leads to a permanent arrest or premature senescence (Bischof, Kirsh et 
al. 2002). After ten days in culture, PML3 overexpressing cells showed all the features of the 
senescence process; they ceased to proliferate at sub-clonfluent densities and became flat and 
enlarged (Fig. 14A). Conversely, cells co-expressing PML3 and MageA2 did not show 
morphological changes respect to control cells (Fig. 14A). MageA2 overexpressing cells 
behaved in a manner that was indistinguishable from control cells. Analysis of the expression 
of senescence-associated β-galactosidase activity (SA-β-Gal), a well known marker of 
senescence, demonstrated that MageA2 expression reduced the levels of SA-β-Gal in PML3 
expressing cells (Fig. 14A and 14B).  Moreover, cells expressing MageA2 and PML3 showed 
higher levels of BrdU incorporation than PML3 overexpressing cells (Fig. 14C). These data 
suggest that PML3-induced senescence is impaired in cells expressing MageA2. 
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Fig. 14: MageA2 impairs PML3 induced senescence
A) Morphology of WI38 normal human fibroblasts infected with empty virus as control (VV), and GFP-MageA2
(MageA2) and/or PML3-expressing retroviruses. Cells were selected for ten days with puromycin and 
hygromycin, fixed and stained for SA-β-Gal activity and photographed under a phase contrast microscopy.
B) Average of cells from “A” that stained positive for SA-β-Gal after counting 200 cells in at least three
independent experiments. C) The same cells from “A” were grown for 3 hours in the presence of BrdU. The
graph shows the average of nuclei positive for BrdU incorporation after counting 200 cells in at least three
independent experiments. D) Western blot from lysates of cells in “A” to confirm the expression of PML and
GFP-MageA2 using specific antibodies. Actin was used as loading control.
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MageA2 relocalizes to PML3 NBs inducing deacetylation of p53 in these structures 
 
Given that p53 becomes acetylated and activated within the PML3 NBs (Pearson, Carbone et 
al. 2000), and because we previously demonstrated the formation of a MageA2/p53 complex, 
we decided to evaluate whether MageA2 could be recruited with p53 to the NBs. 
Immunofluorescence analysis of U2OS cells showed nuclear staining of HA-MageA2 (Fig. 
15A). Co-expression of PML3 with MageA2 induced the recruitment of MageA2 to PML3 
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NBs (Fig. 15B), where endogenous acetylated p53 was also seen to localize (Fig. 15C). 
Interestingly, HA-MageA2 co-localized with endogenous p53 at the NBs (Fig. 15D, left 
panel) and repressed p53 acetylation in these structures (Fig. 15D, right panel), as assessed by 
anti-Ac-p53Lys382 staining.  
 
 
PML3 p53
PML3
PML3 Acp53
PML3
PML3 MageA2
PML3 HA-MageA2
PML3 MageA2 Merge
PML3 + HA-MageA2
p53MageA2
PML3 + HA-MageA2
MageA2 Acp53 Acp53
PML3 + HA-MageA2
A B
C
D
Fig. 15: MageA2 relocalizes to PML nuclear bodies where deacetylates endogenous p53
A) Immunofluorescence of PML3 or HA-MageA2 expressing U2OS cells. PML3 was detected with a monoclonal anti-PML
antibody and MageA2 with an anti-HA monoclonal antibody. B) Immunofluorescence as in “A” but in U2OS cells
co-expressing PML3 and HA-MageA2. C) Acetylation (right panel-Acp53) and co-localization (left panel) of endogenous
p53 and PML3 at NBs. p53 was detected with anti DO-I and Acp53 with an anti-Ac-p53Lys382. D) Immunofluorescence
to visualize the colocalization of endogenous p53, PML3 and MageA2 at NBs (left panel) and the acetylation status of
endogenous p53 in such structures (right panel) using antibodies as in “C”.  
 
 
 
 
                                                                                                                                       Results II 
 - 67 -
MageA2 represses PML3 induced p53 activity  
 
Since relocalization of p53 to the NBs enhances its transactivation function (Fogal, Gostissa 
et al. 2000), we asked whether the expression of MageA2 could affect the activation of p53 by 
PML3. We used the promoter of the p53-target pig3 gene as reporter in luciferase assays 
(PIG3-Luc), since it was shown to be highly responsive to the activation of p53 by PML3 
(Fogal, Gostissa et al. 2000). As expected, expression of MageA2 resulted in reduced activity 
of p53. Interestingly, a strong repressive effect of MageA2 on p53 was also observed when 
PML3 was used to induce p53 transcriptional activity (Fig. 16A). Also in this case MageA2 
showed to be the most efficient MAGE-A member to repress p53 function upon the activation 
by PML3 (Fig. 16B).  
 
 
Fig. 16: MageA2 represses PML3 induced p53 activity
A) Luciferase gene reporter assay in H1299 cells transfected with p53, or in combination with PML3,
in the presence or not of  MageA2 together with the p53-responsive promoter pPIG3LUC. Value
corresponding to p53 transfection was reported to 100. B) p53-specific reporter gene assay as performed
in “A” but using different MageA proteins.
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MAGE-A family members share high levels of sequence identity (Chomez, De Backer et al. 
2001), nonetheless they do not seem to regulate p53 function to the same extent (Fig. 16B and 
Results I – Fig. 2A). Among MAGE-A members, MageA2 and MageA4 are the most 
phylogenetically distant (Chomez, De Backer et al. 2001), however, sequence alignment of 
these two proteins reveal that they are 67 % identical. Based on these evidence and in order to 
give specificity to MageA2 function on p53 and PML3 regulation, we decided to investigate 
the effect of MageA4 on PML3 induced senescence. Surprisingly, MageA4 only slightly 
affected the ability of PML3 to induce senescence, since cells expressing MageA4 and PML3 
showed similar morphological changes than PML3 expressing senescent cells (Fig. 17A), and 
the SA-β-Gal staining and BrdU incorporation were comparable to cells expressing PML3 in 
the presence or not of MageA4 (Fig. 17B and 17C).  
 
It has to be pointed out that, in contrast to MageA2, MageA4 showed a major cytoplasmic 
staining (Fig.18A), and did not co-localized with PML3 and p53 in NBs (Fig. 18B) nor 
induced p53 deacetylation in these structures as MageA2 does (Fig. 18C and see Fig. 15D).  
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Fig. 17: MageA4 does not impair PML3 induced senescence
A) Morphology of WI38 normal human fibroblasts infected with empty virus as control (VV), and GFP-MageA2
(MageA2) or GFP-MageA4 (MageA4) and/or PML3-expressing retroviruses. Cells were selected for ten days
with puromycin and hygromycin, fixed and stained for SA-β-Gal activity and photographed under a phase
contrast microscopy. B) Average of cells from “A” that stained positive for SA-β-Gal after counting 200 cells in
at least three independent experiments. C) The same cells from “A” were grown for 3 hours in the presence of
BrdU. The graph shows the average of nuclei positive for BrdU incorporation after counting 200 cells in at least
three independent experiments. D) Western blot from lysates of cells in “A” to confirm the expression of PML and
GFP-MageA4 using specific antibodies. Actin was used as loading control.
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MageA4PML3 Merge
PML3 + HA-MageA4
PML3
Fig. 18: MageA4 does not relocalize to PML nuclear bodies nor induces deacetylation of 
endogenous p53
A) Immunofluorescence of PML3 or HA-MageA2 or HA-MageA4 expressing U2OS cells. PML3
was detected with a monoclonal anti-PML antibody, MageA2 and MageA4 were identified with an
anti-HA monoclonal antibody. B) Immunofluorescence as in “A” but in U2OS cells co-expressing
PML3 and HA-MageA4. C) Immunofluorescence as in “B” to evaluate the colocalization of
endogenous p53, PML3 and MageA4 at NBs. D) Immunofluorescence as in “B” showing the 
acetylation status of endogenous p53 at NBs. For Acp53 staining was used an anti-Ac-p53Lys382
antibody.
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Finally, we analyzed the ability of MageA2 and MageA4 to bind PML3. Immunoprecipitation 
assays demonstrated that MageA2, but not MageA4, was able to interact with endogenous 
PML (Fig. 19A). For this experiment endogenous PML was immunoprecipitated with a 
monoclonal antibody that recognizes different isoforms of the protein. To determine whether 
MageA2 could bind specifically the PML3 isoform, 293T cells were transfected with PML3 
and HA-MageA2 or HA-MageA4 expressing vectors, and immunoprecipitation using anti-HA 
antibody confirmed that only MageA2 could bind PML3 (Fig. 19B). Interestingly, in vitro 
pull-down experiments using recombinant MageA2 or MageA4 proteins showed direct 
binding between MageA2 and PML3 (Fig. 19C). All these data support the notion that 
MageA2 has a specific regulatory function on PML3 and p53 that is independent on sequence 
similarities with other members of the MAGE-A subfamily. 
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Fig. 19: MageA2 interaction with PML3
A) Immunoprecipitation of endogenous PML in 293T cells transfected with HA-MageA2 or HA-MageA4 using
anti-PML monoclonal antibody or anti-Flag tag monoclonal antibody as control. Western blot was performed
by using polyclonal anti-PML and monoclonal anti-HA antibodies. B) Immunoprecipitation in 293T cells
transfected with PML3 and HA-MageA2 or HA-MageA4 using monoclonal anti-HA antibody. Western blot 
was performed as in A. C) In vitro binding assay using recombinant/purified GST, GST-MageA2 or GST-
MageA4 fusion proteins incubated with in vitro translated 35S-labeled PML3 (IVT PML3).
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MageA2 binds to PML3 in a SUMO1 independent manner 
 
Emerging evidence suggest that the NBs are PML-SUMO structures, where both PML 
sumoylation and PML-SUMO interaction are required for NB formation (Shen, Lin et al. 
2006). PML-SUMO binding is mediated by a short motif (Sumo Binding Motif, SBM) that 
was recently identified in proteins that interact non-covalently with SUMO (Yoon, Kim et al. 
2004). Given the high homology between MAGE-A proteins and their apparent different 
interference with the PML3-p53 axis, we asked whether small differences in the sequence of 
these proteins could account for functional specificity. Sequence analysis of different MAGE-
A proteins (in particular MageA2 and MageA4) evidenced two potential SBMs present in 
MageA2 exclusively but absent in other MAGE-A proteins, as MageA4 (see Fig. 20A and 
20B). 
 
Although we observed direct binding of MageA2 and PML3, we wondered whether the 
presence of SBMs in MageA2 could facilitate the binding to PML3 or influence the repressive 
effect of MageA2 on p53 activation by PML3. To this purpose we generated three different 
MageA2 mutants, bearing mutations in each potential SBM (-SBM I and –SBM II), or 
alternatively mutated in both SBMs (-SBM I/II). Immunoprecipitation assays by using anti-
HA antibody showed no differences in the binding of MageA2 to PML3 (Fig. 21A). 
Moreover, all three mutants demonstrated the same repressive ability on p53 in the presence 
or not of PML3 (Fig. 21B), suggesting that the SBMs in MageA2 are dispensable to its 
binding and function on the PML3-p53 axis. 
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Fig. 20: A) Multiple sequence alignment of MageA2 and MageA4 proteins. B) Schematic 
representation of MageA2 and MageA4 proteins sequences showing the putative SBM 
sequences present in MageA2 but absent in MageA4. 
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Fig. 21: MageA2 SUMO binding motifs are dispensable for MageA2 function
A) Immunoprecipitation of transiently transfected 293T cells with different HA-MageA2 mutants
and PML3 expressing vectors, using anti-HA antibody. Anti-PML polyclonal and anti-HA were
used for Western blot as indicated. B) Luciferase gene reporter assay in H1299 cells transfected
with p53, or in combination with PML3, in the presence or not of different MageA2 SBM mutants
together with the p53-responsive promoter pPIG3LUC. 
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MageA2 affects PML3 sumoylation status 
 
PML is functionally regulated by posttranslational modifications (Bernardi and Pandolfi 
2007). In particular, sumoylation is though to regulate the localization, and stability of PML, 
being one of the nucleation events for NB formation and function of PML (Shen, Lin et al. 
2006). As a second possible mechanism for the repressive effect of MageA2 on PML3 
activity, we therefore investigated whether MageA2 could affect PML3 sumoylation.  
Western blot analysis of 293T cells transfected with HA-MageA2, PML3 and SUMO1 
demonstrated that MageA2 expression impaired the sumoylation levels of PML3 (Fig. 22A). 
To confirm that the bands recognized by anti-SUMO corresponded effectively to sumoylated 
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PML3, we performed the same experiment followed by immunoprecipitation of PML3 
obtaining similar results (Fig. 22B).  
Recently, it has been demonstrated that PML can also be modified by acetylation, and this 
modification seems to favor its subsequent sumoylation (Hayakawa, Abe et al. 2008). In this 
context our results could indicate a possible role of MageA2 in the induction of PML3 
deacetylation probably by recruitment of HDACs (similar to the mechanism observed for 
p53), thus favoring the consequent reduction of PML3 sumoylation levels. 
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Fig.22: MageA2 impairs PML3 sumoylation status
A) Western Blot analysis of 293T cells transfected with PML3 in combination with MageA2 and/or
SUMO1. The membrane was first incubated with an anti-SUMO1 monoclonal antibody, to detect
sumoylated PML3 and subsequently with an anti-PML polyclonal antibody. HA-MageA2 was 
detected with an anti-HA monoclonal antibody. B) Immunoprecipitation performed in 293T cells
transfected as in “A” using an anti-PML monoclonal antibody. Sumoylated and total PML3 was 
detected in western blot with an anti-SUMO1 and anti-PML polyclonal antibody, respectively.
Anti-HA was used to detected HA-MageA2. 
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Altogether the data presented here strongly suggest that MageA2, in contrast to MageA4, is 
able to repress PML3-induced p53 activity in a specific manner, by affecting PML3 mediated 
p53 acetylation at the NBs. The relevance of this effect has been analyzed in a normal cellular 
context, in which PML3 induced premature senescence. In fact, we demonstrated that 
MageA2 impaired the senescence response associated to PML3 expression in normal human 
fibroblast. A possible mechanism for the inhibitory effect of MageA2 on PML3 is that 
MageA2 could interfere with PML3 post-translational modifications such as sumoylation, and 
potentially PML3 acetylation, through recruitment of HDACs as similarly ascertained for p53. 
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Part III: MAGE-I family diversity- MageB2  
 
MageB2 is a nucleolar protein and translocates to the nucleoplasm upon ribotoxic stress 
 
To extend our studies to other MAGE-I family members, we focused our work on the 
MageB2 protein, a member of the MAGE-B subfamily.  
In order to initiate a functional characterization of MageB2 we first analyzed its cellular 
localization. By immunofluorescence experiments in U2OS cells, we observed that MageB2 
localized predominantly in the nucleoli and nucleus of the cells, co-localizing with other 
nucleolar proteins such as nucleolin (NCL) and/or nucleophosmin (NPM) (Fig. 23A). 
Moreover, MageB2 localization seems to be independent of the cellular context, since the 
localization found in U2OS cells was confirmed in different normal and tumor cells (data not 
shown).  
Stress conditions or ribotoxic drugs such as Actinomycin D (ActD) induce nucleolar stress 
with the consequent redistribution of some nucleolar proteins (like ribosomal protein L11, 
ribosomal protein L23 or NCL) to the nucleoplasm (Andersen, Lyon et al. 2002; Zhang, Wolf 
et al. 2003; Dai, Zeng et al. 2004). Upon induction of nucleolar stress by low dose of ActD in 
U2OS cells, HA-MageB2 became relocalized to the nucleoplasm, similar to NCL and NPM 
(Fig. 23B). This behavior was also observed after treatment with other drugs known to 
produce nucleolar disruption, such as low concentration of doxorubicin and UV (Fig. 23B). 
However, using 5-Fluorouridine (5-FUrd), an inhibitor of rRNA processing that also causes 
nucleolar stress, we could observe a nucleoplasm redistribution only for MageB2, whereas 
NCL and NPM retained its original localization (Fig. 23C). This suggested a degree of 
specificity in the behavior of MageB2 in response to various types of nucleolar stress. 
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Fig. 23: MageB2 is a nucleolar protein and translocates to the nucleoplasm upon ribotoxic stress
A) Immunofluorescence of U2OS cells showing localization of transfected HA-MageA2 and HA-MageB2 using an
anti-HA antibody. Monoclonal antibodies for nucleophosmin (NPM) and nucleolin (NCL) were used to visualize
endogenous proteins. B) and C) Immunofluorescence was performed as in “A” but cells were previously treated for
5 hours with the indicated drugs, or UV radiation.  
 
 
MageB2 does not repress p53 transactivation function and confers resistance to 
Actinomycin D in a p53 independent manner 
 
In order to determine whether MageB2 could share redundant functions with MageA2 protein, 
we analyzed the possibility that MageB2 could also regulate p53 transactivation function. 
Luciferase reporter gene assay of a p53 responsive promoter demonstrated that MageB2 was 
not able to regulate p53 function (Fig. 24A). Moreover, immunoprecipitation experiments 
showed no binding between HA-MageB2 and p53 (Fig. 24B). With the purpose of better 
analyze the potential effects of inducible MageB2 expression, we obtained a Ponasterone A 
inducible HA-MageB2-U2OS cell line, which was named U24. Interestingly, HA-MageB2 
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induced expression in U24 cells, correlated with resistance of cells to the ribotoxic drug 
Actinomycin D (ActD). Moreover, HA-MageB2 induction led to a reduction in the apoptotic 
response of the cells after treatment with ActD, as determined by subG1 populations after 
FACS analysis (Fig. 24C). Furthermore, siRNA mediated down-regulation of p53 in U24 
cells did not affect the resistance effect of MageB2 (Fig. 24D), suggesting that MageB2 
confers resistance to ActD in a p53 independent manner. 
 
 
Fig. 24: MageB2 does not regulate p53 function and confers resistance to ActD in a p53 independent manner
A) Luciferase assay in H1299 cells (p53 null) transfected with p53, or in combination with MageB2 and MageA2 together 
with the p53-responsive promoter pG13LUC. B) Immunoprecipitation in H1299 cells transfected with HA-MageB2 or 
HA-MageA2 and p53, using an anti-HA monoclonal antibody. Western blot was performed by using p53 (DO1) and HA
monoclonal antibodies. C) Apoptotic scoring in U24 (HA-MageB2 inducible U2OS) cells expressing (PonA) or not (No PonA)
HA-MageB2, treated for 16 hours with 500 nM ActD. Apoptosis was determined as subG1 populations by FACS analysis
(10.000 counted cells for at least 3 independent experiments). D) Apoptosis determination by Annexin V assay coupled to 
FACS analysis (10.000 counted cells for at least 3 independent experiments). U24 cells transfected with control siRNA (siC)
or p53 siRNA (sip53), were treated as shown in “C” (upper panel). Western blot of U24 cells used for FACS analysis,
anti-p53 (DO-I) and anti-HA antibodies were used to detect p53 and MageB2, respectively (lower panel).
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MageB2 binding to ribonucleoproteins and ribosomal proteins is dependent on RNA 
 
To gain insights into the functional characterization of MageB2, we performed an 
immunoaffinity purification assay to find MageB2 interactors in human cells. To this end, we 
generated a HeLa cell line stably expressing HA-MageB2. Briefly, cells were lysed and 
proteins were immunoprecipitated with an anti-HA monoclonal antibody. The precipitated 
complex was resolved by electrophoresis (SDS-PAGE) and proteins were visualized on the 
gel by colloidal blue coomassie staining. Finally, proteins were identified by in gel digestion 
and mass spectrometry. Sequence analysis of the most prominent bands gave rise to a list of 
MageB2 interactors that included ribonucleoproteins, such as heterogeneous nuclear 
ribonucleoprotein M (hnRPM) and NCL; transcription factors of the general transcription 
machinery (General Transcription Factor II-I, TFII-I); and ribosomal proteins like RP S8, S9, 
S13 and L27a (Fig. 25A). 
Since MageB2 was originally detected as a nucleolar protein and a number of the proteins 
shown to associate with MageB2 localize in the nucleolus participating in the control of RNA 
metabolism, we wondered whether formation of MageB2 protein complexes was dependent 
on RNA. To test this hypotesis, U24 cells lysates were incubated or not with RNase and 
MageB2 protein complexes were subsequently immunoprecipitated. Treatment with RNase 
impaired the binding of almost all ribosomal proteins as assessed by HA-MageB2 
immunoprecipitation of 35S-Methionine pre-labelled proteins  (Fig. 25B), and also the binding 
of NCL to MageB2 by performing the classical IP/western blot assay (Fig. 25C). Moreover, 
MageB2 nucleolar localization was lost after treatment of HeLa cells stably expressing HA-
MageB2 with RNase, an effect that was also observed for NCL (Fig. 25D). These data 
demonstrate that MageB2 could be part of ribonucleoprotein complexes and that its 
localization depends on some specific RNAs, suggesting that MageB2 could participate in 
nucleolar or rRNA metabolism related functions. 
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Fig. 25: MageB2 binds to ribonucleoproteins and ribosomal proteins in a RNA dependent manner
A) SDS-PAGE of HA-MageB2 immunoprecipitated complex from HeLa cells stably expressing HA-MageB2 (B2) or HeLa
control cells (C). Purified proteins were separated and visualized by gel staining with colloidal blue coomassie. Differential
bands between MageB2 and control IPs (1-9) were gel digested and sequenced by mass spectrometry. MW correspond to
molecular weight marker. An anti-HA antibody was used in the immunoprecipitation (left panel). Right panel shows the list
of the proteins that were precipitated and identified by excision of the bands showed on the left panel. B) IP of U24 cells
with an anti-HA antibody was performed after pulse labeling of the cells with S35-Methionine for 16 hours. Prior to IP cell
lysates were treated or not with RNase for 30 minutes. Immunoprecipitated complex was resolved by SDS-PAGE and
visualized by autoradiography. C) IP as in “B” but using HeLa HA-MageB2 stable cells. After IP endogenous nucleolin
was visualized with an anti-nucleolin monoclonal antibody by western blot. D) HA-MageB2 and endogenous nucleolin
localization after treatment of cells with RNAse. Immunofluorescence was performed in HA-MageB2 HeLa cells.
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MageB2 stimulates E2F1 activity and relocalizes pRB to nucleoli 
 
During the characterization of MageB2 we observed that although it failed to regulate p53 
transcriptional activity, it was able to significantly activate the transactivation function of the 
E2F1 transcription factor, in luciferase reporter gene assays using an E2F1 responsive 
promoter as reporter and growing amounts of MageB2 (Fig. 26A). In addition, MageB2 
expression impaired the repressive effect of pRB on E2F1 activity (Fig. 26A). To determine 
whether  MageB2 could inhibit the function of pRB by affecting its cellular localization, we 
performed immunofluorescence experiments. pRB is generally localized in the nucleus of the 
cell, however co-expression of pRB with HA-MageB2 induced pRB relocalization to the 
nucleolus (Fig. 26B, upper panel). Treatment of cells with a buffer that eliminates soluble 
proteins (CSK buffer), demonstrated more clearly the relocalization effect of MageB2 on pRB 
(Fig. 26B, lower panel). Altogether these data suggest that MageB2 could induce E2F1 
transactivation function by sequestering pRB to the nucleolus. 
 
It has been reported that E2F1 participates in the induction of rRNA transcription (Ayrault, 
Andrique et al. 2006). Since we showed that MageB2 enhances the transcriptional activity of 
E2F1, reporter gene assays were performed to explore whether MageB2 could modulate the 
activity of E2F1 using the rRNA promoter-Luc construct (pHrD-Luc). Expression of E2F1 
produced the expected increase in the activity of the rRNA promoter, while co-expression of 
MageB2 led to a further enhancement of E2F1 activity on this promoter (Fig. 27A). 
Moreover, analysis of newly transcribed RNA by FUrd incorporation into nascent RNA 
revealed that E2F1 was able to increase RNA transcription as was observed by 
immunofluorescence using antibodies against halogenated nucleotides (Fig. 27B, upper 
panel). Interestingly, co-expression of E2F1 with HA-MageB2 resulted in an increased RNA 
transcription induction by E2F1 (Fig. 27B, lower panel). However, the single expression of 
MageB2 was not sufficient to stimulate RNA transcription (Fig. 27B, middle panel).  
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Fig. 26: MageB2 stimulates E2F1 activity and relocalizes pRB to the nucleolus
A) Luciferase assay in U2OS cells transfected with E2F1 in the presence or not of pRB, and growing
quantities of MageB2 using an E2F1-responsive promoter. B) Upper panel, Immunofluorescence in U2OS 
cells transfected with pRB and/or HA-MageB2, using anti-pRB and anti-HA monoclonal antibodies. 
Lower panel, similar to upper panel but cells were treated with CSK buffer to eliminate soluble proteins
prior to fixation.
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Fig. 27: MageB2 colaborates with E2F1 to induce the transcription of rRNA
A) Luciferase assay in H1299 cells transfected with E2F1 in the presence or not of  MageB2 using the 
promoter of the human ribosomal DNA (pHrD) as reporter. B) Analysis of newly transcribed RNA in U2OS
cells transiently transfected with E2F1 (upper panel), HA-MageB2 (middle panel) or the combination of
them (lower panel). Cells were pulsed for 1 hour with 2 mM 5-FUrd, and nascent RNA visualized with
antibodies against halogenated nucleotides (anti-BrdU). Anti-E2F1 and anti-HA monoclonal antibodies were
used to detect E2F1 and MageB2, respectively.
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This part of the work comprises a preliminary characterization of MageB2 protein, which 
clearly demonstrates its functional difference with respect to MageA2 protein. All the data 
obtained here suggest that MageB2 could function as a positive regulator of proliferation, 
probably by regulating the E2F1-pRB pathway and/or participating in rRNA metabolism 
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processes. Future experiments will be focused on determining the mechanism by which 
MageB2 expression controls such cellular functions.  
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5. Discussion  
 
MAGE genes belong to a family of highly conserved genes sharing significant level of 
sequence homology (Chomez, De Backer et al. 2001). Type I MAGE genes are part of a 
growing group of genes termed Cancer Testis Antigens (CTAs), so named by their restricted 
expression in tumor and male germ cells (Simpson, Caballero et al. 2005). Expression of 
MAGE-I genes seems to be an early event in tumorigenesis and correlates with genome-wide 
hypomethylation, a frequently observed epigenetic event in carcinogenesis (De Smet, Lurquin 
et al. 1999). Since the discovery of MageA1 in the early 90’s, the study of MAGE-I genes 
was focused on their application in cancer immunotherapy; the analysis of their biological 
functions remained poorly investigated. Due to their sequence homology, MAGE-I proteins 
were considered functionally redundant proteins: their expression being confined to their use 
as cancer-markers. Emerging evidence suggest however that MAGE-I proteins could display 
specific roles along the complexity of tumor progression.  
In this Thesis, the aim was to functionally characterize specific MAGE-I genes, in particular 
MageA2 and MageB2 genes, in order to demonstrate their functional specificity. The main 
aim was to place their roles within different known pathways: the clearest picture emerging 
for the specificity of MageA2 on the p53 pathway, and the promising, still preliminary, 
activity of MageB2 in the Rb/E2F1 pathway. 
 
 
MageA2 targets p53 transactivation function and confers resistance to chemotherapeutic 
agents 
 
The p53 protein is a tumor suppressor, that is activated in response to several stimuli to 
regulate a multitude of cellular outcomes, which finally ensure the maintenance of genomic 
stability and prevent cell transformation. The relevance of p53 function is highlighted by the 
fact that the p53 gene is mutated in more than 50% of tumors or alternatively its function is 
affected by many different means in tumors expressing wild type p53. Moreover, p53 function 
is tightly regulated through different mechanisms, including post-translational modifications, 
cellular localization or the cell cycle phase (Murray-Zmijewski, Slee et al. 2008). 
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The first evidence we obtained that MAGE-A proteins regulate p53 function, came from 
experiments in which we observed that in tumors bearing wild type p53, the levels of MAGE-
A genes correlate with resistance to chemotherapeutic drugs. More detailed experimental 
approaches demonstrated that all MAGE-A genes analyzed (MageA1, A2 and A6) are able to 
repress p53 transactivation function, but in particular MageA2 showed the strongest 
repressive activity. The differential response of MAGE-A proteins on p53 function seems to 
correlate with the different ability of these proteins to bind p53. Actually, we observed that 
there is a direct correlation between binding of MAGE-A proteins to p53 and their ability to 
repress its transactivation function. For instance, MageA2 binds and repress p53 more 
strongly than MageA1 or MageA6, while MageA4 does not bind nor repress p53 function 
(data not shown). MageA2 repressive effect on p53 also displays specificity with respect to 
the family members of p53 transcription factors, since we observed that MageA2 can repress 
p53 and p73, but not p63. This repressive effect seems to be associated with the ability of 
MageA2 to physically bind the specific transcription factor: while MageA2 can efficiently 
interact both with p53 and p73, it fails to associate with p63 (data not shown). This suggests 
that the specificity of MageA2 for the p53 family members is based on a direct link between 
protein-protein interaction and transcriptional repression. 
Analysis of p53 endogenous targets demonstrated that expression of MageA2 leads to an 
impaired transcription of p53 targets, such as p21 and bax genes, after treatment of cells with 
etoposide (ET), without affecting p53 protein levels, and these effects correlate with a reduced 
ET-induced growth arrest and apoptosis. Conversely, siRNA mediated knock-down of 
MageA2 expression, was shown to restore the p53 dependent response. Moreover, expression 
of MageA2 in p53 null cell line does not induce survival after ET treatment, demonstrating 
the p53 dependence for MAGE-A effect. 
In order to gain insights into the mechanism responsible for the MageA2 repressive effect on 
p53, the p53 post-translational modifications were analyzed showing that MageA2 represses 
damage-induced p53 acetylation, without affecting p53 phosphorylation on Ser15.  
The reduction of p53 acetylation levels after expression of MageA2 seems to be dependent on 
the recruitment and assembling of HDAC3/p53 complexes. In fact immunoprecipitation and 
in vitro binding assays demonstrated that MageA2 binds directly both p53 and HDAC3, and 
that the p53 DBD is involved in this interaction. In addition, the deacetylating function of 
MageA2/HDAC3 complex remains fully active and it is found associated to p53 on p53 
targets promoters. This suggests that p53/MageA2/HDAC3 complex can regulate other 
acetylation-dependent substrates such as nucleosomal histones. In fact, the transcriptional 
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activity of a non-acetylable p53 mutant (p539KR) is similarly repressed by MageA2. Finally, 
ChIP assays demonstrated that MageA2 does not affect p53 binding to chromatin upon 
damage, but instead favors the recruitment of HDAC3 and the consequent deacetylation of 
histones on p53 binding sites. All these data support the notion that the main mechanism by 
which MageA2 targets p53 activity is the induction of histone hypoacetylation on the 
chromatin surrounding p53 binding sites, in addition to deacetylating p53 itself, by selectively 
recruiting HDAC3. 
The relevance of MageA2 expression on p53 function was highlighted by using cell lines 
obtained from melanoma biopsies expressing high levels of MAGE-A and wild type p53. In 
this context we confirmed that the DNA damage response is impaired in melanoma cells 
expressing high MAGE-A levels due to MageA2-dependent impairment of p53 transcriptional 
activity. Moreover, the chemoresistance effects of MAGE-A expression could be reverted by 
using inhibitors of HDACs, such as TSA. Finally, melanoma cell lines expressing high levels 
of MAGE-A but harboring mutant p53, or where p53 was depleted by retrovirus transducing 
siRNA, are refractory to ET/TSA treatment.  
All these data demonstrate that MageA2 has a specific repressive function on p53, that relies 
on its ability to recruit HDACs, consequently inducing deacetylation of p53 and histones 
surrounding p53 binding sites thus conferring resistance to chemotherapeutic drugs. 
 
 
MageA2 represses PML3-induced p53 senescence 
 
The p53 tumor suppressor is a highly regulated protein. Several proteins were shown to 
specifically regulate p53 function. PML3 is such a p53 regulator, being responsible for 
recruiting p53 to PML-NBs, where it is stabilized and transcriptionally activated (Bode and 
Dong 2004). 
The second part of the Thesis was devoted to analyze whether MageA2, by regulating p53 
primarily via acetylation, could also participate in the control of PML3-induced p53 
acetylation, a process that has been correlated with the induction of premature cellular 
senescence (Ferbeyre, de Stanchina et al. 2000; Pearson, Carbone et al. 2000).  
Retroviral mediated transduction of normal human fibroblasts with PML3 results in the 
acquisition of a senescent phenotype as evidenced by the typical morphological changes, 
expression of SA-Gal and reduced incorporation of BrdU. Co-infection of PML3 with 
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MageA2 retroviruses resulted in markedly reduced signs of senescence, suggesting that 
MageA2 can prevent PML3 induced senescence. 
Moreover, immunofluorescence assays demonstrated that MageA2 is recruited to PML-NBs 
where it co-localizes with endogenous p53, inducing p53 deacetylation in such structures. 
This effect could also be explained by a direct effect of MageA2 on PML3 restricting its 
ability to induce p53 mediated senescence. Importantly, MageA2 markedly represses PML3-
induced p53 transactivation activity on a p53 responsive promoter, previously shown to be 
specifically regulated by p53 in response to PML3 expression. Also in this case, MageA2 is 
again the strongest repressor with respect to the other MAGE-A proteins assayed. 
The most divergent MAGE-A proteins (MageA2 and MageA4: 67% identical) behave quite 
differently with respect to the PML3/p53 regulatory axis. In fact, MageA4 is incapable of 
interfering with the PML3-induced senescence response; cellular morphology, SA-β-Gal 
expression and BrdU incorporation are unaffected upon co-expression of MageA4 and PML3. 
Furthermore, MageA4 does not relocalize to PML-NBs, does not affect p53 transactivation 
function nor modifies p53 acetylation status. Moreover, contrary to MageA2, MageA4 is not 
able to interact with PML3 as shown both by in vivo and in vitro pull-down assays. 
In silico analysis of the amino acid sequences of MAGE-A proteins revealed that MageA2 
contains two potential SUMO binding motifs (SBMs) that are not present in MageA4. SUMO 
modification and binding to PML were shown to be required for the arrangement of PML-
NBs (Shen, Lin et al. 2006) and for the function of PML3 on p53 activity (Fogal, Gostissa et 
al. 2000). To evaluate a potential involvement of SBMs in the mechanism of MageA2 
repressive effect on PML3 function, we generated three different MageA2 constructs where 
the hydrophobic Ile and/or Val residues in the MageA2 SBMs were replaced with Ala 
residues. The respective mutants were analyzed for binding to PML3 by immunoprecipitation 
assays demonstrating that MageA2 SBMs are dispensable for binding to PML3. In fact, 
MageA2-SBMs mutants bind PML3 and are capable of repressing PML3-induced p53 
transactivation function equally to wild type MageA2. These data suggest that the mechanism 
responsible for MageA2 dependent repression of PML3-induced p53 function is not 
dependent on the binding of MageA2 to sumoylated PML3.  
A second possible mechanism examined, was the possibility that MageA2 could interfere with 
PML3 function on p53 through the balance of post-translational modifications of PML3. In 
fact, MageA2 expression results in significantly reduced levels of PML3 sumoylation. The 
correct PML3 sumoylation is in fact necessary for PML-NBs formation and p53 activation. 
Impairment of PML3 sumoylation by MageA2 could therefore constitute a potential 
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mechanism for the observed reduction of PML3 induced senescence in MageA2 expressing 
cells. Interestingly, a very recent work has demonstrated that PML3 acetylation favors 
subsequent PML3 sumoylation (Hayakawa, Abe et al. 2008). We are currently evaluating a 
potential role of MageA2 in the induction of PML3 deacetylation probably through the 
recruitment of HDACs as demonstrated for p53. This could therefore constitute part of the 
mechanism responsible for the consequent reduction on PML3 sumoylation which leads to a 
defective p53 activation within NBs.  
Altogether the data presented in this second part support the notion that MageA2 specifically 
represses PML3-induced p53 activity, by interfering with the ability of PML3 to stimulate 
p53 acetylation at the NBs. The significance of the effect of MageA2 on PML3 activity has 
been analyzed in a normal cellular context (human diploid fibroblasts), in which PML3 was 
observed to induce premature senescence.  
MageA2 expression can therefore control a specific step in carcinogenesis, namely the PML3-
p53 axis responsible for commitment to cellular senescence, which constitutes one of the 
critical barriers for cellular transformation.  
 
 
MageB2 has nucleolar associated functions, which are independent of p53 and possibly 
dependent on RB/E2F1 
  
In the last part of this Thesis we have focused our work on another MAGE-I family member, 
the MageB2 protein. MAGE-B genes share 45-63% sequence identity with MAGE-A genes, 
and so far none of them has been yet characterized. Immunofluorescence experiments 
demonstrated that MageB2 shows a specific nucleolar localization. The nucleolus is a 
dynamic structure that responds to different stresses through a spatial reorganization of the 
nucleolar proteins. This leads to a rapid variation on nucleolar functions such as rRNA 
transcription, pre-rRNA processing and ribosome subunits assembly (Lam, Trinkle-Mulcahy 
et al. 2005). We observed that upon nucleolar disruption by treatment with different drugs 
such as Actinomycin D, low doses of doxorubicin or UV light, MageB2 behaves similarly to 
those nucleolar proteins (nucleolin (NCL) and nucleophosmin (NPM)) showing a rapid 
redistribution to the nucleoplasm. Nevertheless, treatment with 5-fluorouridine produces a 
specific redistribution of MageB2 to the nucleoplasm, without affecting the localization of 
NCL or NPM. These data suggest that MageB2 could be even more sensitive in the response 
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to specific ribotoxic drugs, since its leaves the nucleolus faster than nucleolin and 
nucleophosmin.    
We could determine that MageB2 does not affect p53 transactivation function as assessed by 
reporter-gene assays. Moreover, immunoprecipitation approaches indicate that MageB2 is not 
able to bind p53. Interestingly, we were able to show that MageB2 confers resistance to the 
ribotoxic drug Actinomycin D in a p53 independent manner.  
As part of the characterization of MageB2 we performed a proteomic approach to identify 
MageB2 interactors. Immunoaffinity purification of MageB2 molecular complexes 
demonstrated that MageB2 interacts with different ribonucleoproteins, such as heterogeneous 
nuclear ribonucleoprotein M (hnRPM) and NCL; transcription factors of the general 
transcription machinery (General Transcription Factor II-I, TFII-I); and ribosomal proteins 
like ribosomal protein S8, S9, S13 and L27a. For some of these proteins the binding to 
MageB2 seems to be dependent on RNA. In fact, MageB2 nucleolar localization itself 
depends on RNA, since after treatment of cells with RNase, MageB2 completely looses its 
nucleolar localization.  
Another specific feature of MageB2 that clearly differentiates it from MAGE-A proteins, is 
the fact that MageB2 induces the transactivation activity of E2F1. E2F1 transactivation 
activity is required for the transcription of genes involved in the G1/S transition, and hence, 
for the correct progression through the cell-cycle. The transactivating activity of E2F1 is 
repressed through binding to pRB, which once phosphorylated by CDKs releases E2F1, 
which is then able to activate its target genes (Coller 2007). Reporter gene assays with E2F1 
responsive promoters suggest that MageB2 collaborates with E2F1 in the transactivation of 
such promoters and inhibits in part the repressive effect of pRB on E2F1 activity, probably by 
promoting pRB relocalization to the nucleoli, as observed in immunofluorescence assays. 
Interestingly, although MageB2 is not able to induce the transcription of rDNA by itself, it 
enhances E2F1 activity on the rDNA promoter as assessed by reporter gene assays and by the 
analysis of newly transcribed RNA.  
The initial characterization data of MageB2, indicate that MageB2 seems to display functions 
related to its nucleolar localization. With respect to the proteins that it binds and the 
requirement of RNA for these interactions, it can be suggested that such functions could be 
related to the control of mechanisms such as RNA metabolism or protein synthesis. Moreover, 
since we observed that MageB2 induces E2F1 transactivation function, it could also have a 
role in the regulation of cell proliferation. Future efforts will be devoted to better clarify the 
specific roles of MageB2 both in nucleolar functions and consequent effects on cell 
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proliferation as well as the mechanisms by which MageB2 is capable of performing such 
functions. 
 
Altogether the data presented in this Thesis strongly support the notion that, despite a 
significant level of sequence homology shared by the members of MAGE-I family, these 
proteins do not have redundant functions but have specificities with respect to functional 
pathways.  
An important point to consider in the study of MAGE-I proteins is the mechanism responsible 
for the expression of these genes. MAGE-I genes expression seems to be an early event in 
tumorigenesis as well as during gametogenesis, both processes sharing important and 
interesting similarities. In fact, the discovery of a growing number of proteins that appear to 
be present only in germ cells, trophoblasts and tumors (the cancer testis antigens genes that 
include MAGE-I genes), led to the theory that aberrant expression of germline genes in cancer 
reflects the activation of the silenced gametogenic program in somatic cells, and that this 
acquisition could constitute one of the driving forces of tumorigenesis (Simpson, Caballero et 
al. 2005; Old 2007). Actually, recapitulation of portions of the germline gene expression 
program during oncogenesis, might contribute characteristic features to the neoplastic 
phenotype, including immortality, invasiveness, immune evasion, apoptosis resistance, 
hypomethylation. Normally oncogenic proliferative signals are coupled to a variety of 
growth-inhibitory processes, such as the induction of apoptosis, differentiation or senescence, 
each of which restricts subsequent clonal expansion and neoplastic evolution. Tumor 
progression occurs only in the very rare instances where these growth-inhibitory mechanisms 
are contrasted by compensatory mutations (Evan and Vousden 2001). Therefore, mutation or 
epigenetic activation of master switches orchestrating gametogenesis, could provide the 
cancer cell with a global compensatory behavior that could enforce the accumulated 
oncogenic events to become fixed and fully functional (Old 2007). Hypomethylation is known 
to accompany and characterize gametogenesis and carcinogenesis and is clearly involved in 
the anomalous expression of MAGE-I genes. The functional role of MAGE-I genes could 
therefore be selected within the global gametogenic switch program. 
Although the role of MAGE-I genes is only beginning to be explored, emerging data suggest 
that they could have functions favoring the malignant phenotype, e.g. resistance to apoptosis, 
chemotherapy sensitivity/resistance, migration, proliferation. (Simpson, Caballero et al. 
2005). Moreover, even though the expression of individual MAGE-I genes varies greatly 
among tumor types, they are frequently co-expressed in the same tumor, suggesting a possible 
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cooperative effect through the control of different processes acting synergically to 
enforce/maintain the full transformation spectrum.  
The experiments shown in this Thesis demonstrate how the expression of MageA2 or 
MageB2 could confer resistance to apoptosis upon chemotherapeutic drugs treatments, by 
respectively p53 dependent and independent mechanisms. After the publication of our data 
indicating that MAGE-A proteins regulate p53 activity (Monte, Simonatto et al. 2006), other 
groups have started to study MAGE-I genes in different tumor models. Yang et al. have 
reported that siRNA mediated repression of MAGE-I proteins (MAGE-A, -B and –C) induces 
apoptosis and increases acetylation and activity of p53, and demonstrated that in the case of 
MAGE-A the induction of apoptosis requires p53 (Yang, O'Herrin et al. 2007).  Zhu et al. 
showed that in particular MageA3 down-regulation results in p53 transcriptional induction in 
pituitary tumors (Zhu, Asa et al. 2008). Liu et al. demonstrated that overexpression of 
MageA3 leads to p21 down-regulation, accelerated cell-cycle progression, increased cell 
migration rate, and invasion in a murine model of thyroid cancer (Liu, Cheng et al. 2008).  
We observed that the mechanism responsible for p53 repression by MageA2 is through the 
association with HDACs. Previous studies demonstrated that MageA1 acts as a transcriptional 
repressor by binding to SKIP and recruiting HDAC1 (Laduron, Deplus et al. 2004). 
Nevertheless, we have not observed strong repression of p53 by MageA1, this observation 
agreeing with our hypothesis that the differences in the sequence of MAGE-I proteins should 
account for functional and quantitative specificity. This hypothesis is also supported by the 
fact that we observed that MageA4 does not share any functional feature with MageA2. 
Actually, it has been demonstrated that MageA4 can display anti-oncogenic functions by 
blocking the activity of gankyrin and the transcription factor Miz-1, leading to apoptosis 
(Nagao, Higashitsuji et al. 2003; Sakurai, Itoh et al. 2004; Peikert, Specks et al. 2006). So far, 
among characterized MAGE-A members, MageA4 is the only one that seems to behave as a 
tumor suppressor, while the other analyzed MAGE-A proteins (for instance MageA1, 
MageA2 and MageA3) have reported pro-oncogenic functions.  
We have also demonstrated that MageA2 impairs PML3 induced senescence by repressing 
PML3-induced p53 activity. It will be interesting to analyze a possible involvement of 
MageA2 in bypassing senescence induced by oncogenes such as Ras through mechanisms 
dependent on p53 or by affecting the DNA-damage response. On the other hand, our results 
suggest that MageB2 could exert functions related to cell-cycle progression and proliferation 
through control of the E2F1-pRB pathway.  
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Considering the complex scenario, where the coordinated expression of highly similar 
proteins could perform different functions, it is possible to hypothesize that the early 
expression of MageA2 and MageB2 could be involved in bypassing senescence by affecting 
both PML-p53 and Rb-E2F axis, respectively. Alternatively, in established tumors the 
expression of MageA2 and MageB2 could confer cells the ability to survive and resist 
chemotherapy (Fig. X). 
Since the discovery of MAGE-A proteins, continuous efforts were concentrated in 
understanding  the mechanisms responsible for the expression of these genes in tumors and 
the prognostic relevance of their differential expression. Due to their large number and 
sequence similarities, MAGE-I proteins have been mostly considered as epiphenomenon of 
cell transformation and used as targets for anti-cancer immunotherapies. Evidence presented 
in this Thesis, point to consider the specific cellular functions and the respective pathways 
that are targeted by this vast and heterogeneous family of genes. This will generate critical 
knowledge to potentially exploit MAGE-I genes as targets to be specifically inactivated in 
cancer cells.  
 
 
Mage-B2
X chromosome
Mage-A2 p53
SENESCENCE
APOPTOSIS
(DNA-damage response)
pRb
PROLIFERATION
SENESCENCE
Fig. X: Schematic representation showing differences between the MAGE-I genes analyzed in the present work 
 
 
 
 
                                                                                                                 Materials and methods 
 - 95 -
 
 
6. Materials and methods 
 
Cell lines and treatments 
U2OS is a human osteosarcoma cell line; 293T is a derivative of the 293 kidney carcinoma 
cell line constitutively expressing the simian virus 40 (SV40) large T antigen; H1299 are 
human p53-null non–small cell lung carcinoma cells; HeLa are human cervical carcinoma 
cells; SaoS-2 is a human p53-null osteosarcoma cell line; 15392M and 13923M are human 
melanoma cell lines obtained from melanoma biopsies expressing, low and high, MAGE-A 
levels, respectively; BE and SK-Mel-28 are human melanoma cell lines bearing mutated p53; 
Wi38 are human primary lung fibroblasts. All cell lines were routinely cultured at 37°C in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% foetal bovine serum 
(FBS), penicillin (100 U/ml) and streptomycin (100 µg/ml), with the exception of H1299, 
15392M, 13923M, BE and SK-Mel-28 cell lines that were cultured in RPMI-1640 medium. 
M20 and U24 cell lines were maintained in medium containing zeocin and G418 (400 µg/ml). 
To induce the expression of HA-MageA2 or HA-MageB2, respectively, Ponasterone A, a 
synthetic analogue of ecdysone (Invitrogen) was added to the culture medium at a final 
concentration of 5 µM for 24 hr. Cisplatin, Etoposide, Trichostatin A, Actinomycin D, 
Doxorubicin and 5-Fluorouridine were purchased from Sigma and were used at the 
concentrations and for the indicated time. 
 
Transfections and plasmids 
Cells were transfected using Calcium Phosphate method, Lipofectamine 2000 Reagent 
(Invitrogen) or FuGENE 6 (Roche) according to the manufacturer’s instructions. Unless 
stated otherwise, cells were analyzed 24 hr after transfection. MageA1, MageA2, MageA4, 
MageA6, p53, p53 deletion mutants, MageA2-SBM mutants, and MageB2 were HA tagged 
and cloned in pCDNA3 (Invitrogen). MageA2-SBM mutants were obtained by substitution of 
valine and/or isoleucine residues in the putative SBM sequences for alanines. His-MageA2 
was cloned in pCDNA3.1 (Invitrogen). GST-p53, GST-MageA2, and GST-MageA4 were 
obtained by subcloning in pGEX-4T1 (Pharmacia). Flag-HDAC3 was obtained from 
C.Brancolini, DSTB University of Udine. Flag-MageA2 was obtained by subcloning in 
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p3XFLAG-CMV-10 (Sigma). pCDNA3-PML3 was kindly provided by Dr. Pandolfi PP. 
pCMV-HA-E2F1, pCMV-pRB were kindly provided by Dr. Giacca M. 
For MAGE-I silencing we used a pool of four siRNA, based on a highly conserved MageA2 
sequence (SMARTpool, Dharmacon Research). This reagent was able to knock-down all 
tested MAGE-I genes (MageA1, MageA2, MageA3, MageA6, data not shown). The control 
siRNA used was AACCUUUUUUUUUGGGGAAAA (siCONT). p53 silencing was from 
MWG and the mRNA target sequence was AAGACUCCAGUGGUAAUCUACTT. HDAC1 
and HDAC3 siRNAs were from MWG. HDAC1 siRNA was 
GCAGAUGCAGAGAUUCAACTT and HDAC3 siRNA was 
GAUGCUGAACCAUGCACCUTT. Cells in mid-log growth phase were transfected with 
siRNA’s using Oligofectamine Reagent (Invitrogen) or X-tremeGENE siRNA Transfection 
Reagent (Roche) as recommended by the manufacturer. Cells transfected with siRNA were 
analyzed after 36 hr. 
 
Retroviral-mediated gene transfer 
For retroviral infection, amphotrophic retrovirus packaging 293 cells were transfected by 
calcium-phosphate precipitation with the corresponding retroviral plasmid for 16 hr at 37°C. 
After 48 hr at 32°C, the virus-containing medium was filtered (0,45 µm filter) and 
supplemented with 4 µg/ml polybrene (Sigma). The culture medium of target cells was 
replaced by the appropriate viral supernatant, and then the cultures plates were centrifuged for 
1 hr at 1500 rpm and incubated for 16-24 hr at 32°C. Finally, infected cell populations were 
purified using the appropriate selection: 2 µg/ml puromycin (Sigma) or 75 µg/ml hygromycin 
(Roche). Retroviral plasmids used were: pSuperRetro-Puro (pSR) vector (Oligoengine) 
encoding a sequence (5’-AACCAGCTATGTGAAAGTC-3’) (pSRMage) with 100% 
matching to several MageA genes (A1, A2, A3, A4, A6, A7, A8 and A12). p53 activity was 
controlled by using pBabe-Hygro-EGFP-p53OD. pWZL-Hygro-PML3 was kindly provided 
by Dr. Ferbeyre, G. pLPC-EGF-MageA2 and pLPC-EGF-MageA4 were obtained by 
subcloning MageA2 and MageA4 cDNAs into pLPC-EGFP (Puromycin resistance). 
 
Western blot analysis and antibodies 
Western blot analysis was performed according to the standard procedures using the 
following primary antibodies: For p53: DO1, anti-p53 monoclonal (Santa Cruz 
Biotechnology), anti-acetyl p53 (Lys382) and anti-phospho p53 (Ser15) (16G8) (Cell 
Signaling). For Mage detection, affinity purified anti-MageA6 raised against GST-MageA6, 
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FL-309 anti-MAGE polyclonal antibody (Santa Cruz Biotechnology) or anti-Mage 57B 
monoclonal antibody (a gift from Spagnoli G., Basel). Other primary antibodies: anti-actin 
polyclonal antibody (Sigma), anti-Bax polyclonal antibody (Cell Signaling), anti-p21Waf1 
polyclonal antibody (Santa Cruz Biotechnology), anti-HDAC3 polyclonal antibody (Cell 
Signaling), anti-HDAC1 polyclonal antibody (Cell Signaling), anti-PML polyclonal and 
monoclonal (PG-M3) antibodies (Santa Cruz Biotechnology), anti-SUMO1 monoclonal 
antibody (Zymed Laboratories), anti-NCL monoclonal antibody (Zymed Laboratories), anti-
NPM monoclonal antibody (Zymed Laboratories), anti-pRB monoclonal antibody (Santa 
Cruz Biotechnology). For tags: anti-HA 12CA5 monoclonal antibody (Roche), anti-Flag M2 
monoclonal antibody (Sigma), affinity purified anti-GFP raised against GST-GFP. 
 
Immunoprecipitation 
Cells were harvested in ice-cold lysis buffer containing 50 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 1% Nonidet P-40 (NP-40), 0.1 mM sodium orthovanadate, 2 mM dithiothreitol (DTT), 
0.1 mM phenylmethylsulfonyl fluoride (PMSF), 5 mM EDTA and Protease Inhibitor Cocktail 
(Sigma). After 10 min of rocking at 4°C, lysates were clarified by centrifugation and 
precleared with 25 µl of  Protein A-Sepharose CL-4B or GammaBind G-Sepharose 
(Amersham Biosciences). Then, antibody prebound to 25 µl of Protein A-Sepharose CL-4B or 
GammaBind G-Sepharose was added and incubated at 4°C for 4 hr. The resin was then 
washed and bound proteins were eluted in SDS-PAGE sample buffer. For 
immunoprecipitation of endogenous PML, cells were harvested in RIPA buffer containing 50 
mM Tris-HCl pH 7.8, 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.5% NP-40, 0.2% 
deoxycholic acid, 0.1 mM sodium orthovanadate, 0.1 mM PMSF and Protease inhibitor 
cocktail (Sigma). For PML post-translational modifications analysis RIPA buffer was 
supplemented with 10 mM N-ethylmaleimide (NEM) for sumoylation analysis, or 5 mM 
butyric acid for acetylation analysis. Anti-PML monoclonal (PG-M3) antibody was prebound 
to Protein G-Sepharose and incubated with cells lysates for 16 hr at 4°C. 
For in vivo labeling of proteins, cells were grown for 24 hr in complete medium, then it was 
replaced with methionine and cysteine free DMEM for 1 hr and 20 µCi/ml 35S-Methionine 
(Amersham Biosciences) was then added to the medium for 16 hr. For RNase treatments, cell 
lysates were incubated with 50U RNase ONE (Promega) for 30 min at 37°C prior to 
immunoprecipitation. 
 
                                                                                                                 Materials and methods 
 - 98 -
In vitro pull-down assays 
35S-labeled proteins were in vitro translated using TNT Quick Coupled 
Transcription/Translation System (in vitro protein expression) (Promega) and incubated with 
purified GST, GST-MageA2, GST-MageA4 or GST-p53 (immobilized on glutathione-
Sepharose 4B beads, Amersham Biosciences) in pull-down buffer (PBS, 0.1% NP-40, 10% 
Glycerol, 0.1 mM PMSF and Protease Inhibitor Cocktail). Bound proteins were eluted and 
resolved by SDS-PAGE. 
 
Transient transactivation assays 
For p53 reporters: cells were co-transfected in a 24-well plate with 100 ng of pG13LUC (an 
artificial promoter made of a tandem repeat of a fragment of the p21 promoter), p21LUC, 
Mdm2LUC, BaxLUC or PIG3LUC reporter constructs together with 50 ng of pCDNA3-p53 
or pCDNA3-p539KR, either alone or with 150 ng of pCDNA3-HA-MageAs, pCDNA3-HA-
MageB2 or pCDNA3-PML3 constructs. 
For E2F1 reporters: cells were co-transfected in a 24-well plate with 500 ng of pGL3-TATA-
6XE2F1-LUC reporter together with 10 ng of pCMV-HA-E2F1 and 10 ng pCMV-Myc-DP1, 
either alone or with 300 ng of pCDNA3-HA-MageB2 or 50 ng of pCMV-pRB. For the 
hrDNA reporter, cells were co-transfected with 200 ng of pIRES-LUC or pHrD-IRES-LUC, 
either alone or with 300 ng of pCMV-HA-E2F1 or 500 ng of pCDNA3-HA-MageB2. In this 
case, luciferase activity corresponded to the ratio (pHrD-IRES-LUC/pRL to pIRES-
LUC/pRL) calculated from each set of experiments. 
For normalization of transfection efficiency, 10 ng of pRL-CMV reporter (Promega), 
constitutively expressing the Renilla reniformis luciferase, was included. After 24 hrs, cells 
were lysed and assayed for luciferase activity using the Dual Luciferase kit (Promega).  
 
Immunofluorescence analysis 
Cells were plated on glass coverslips in 3 cm culture dishes. After washing with PBS, cells 
were fixed in 3% paraformaldehyde in PBS, treated with 1% glycine in PBS, and 
permeabilized in 0.1% Triton X-100 in PBS. The staining was performed using specific 
antibodies incubated in 5% bovine serum albumin in PBS at 37°C followed by fluorescein 
isothiocyanate or tetramethylrhodamine isothiocyanate-conjugated secondary antibodies 
(Sigma) as indicated. Treatment with CSK buffer (100 mM NaCl, 300 mM sucrose, 10 mM 
Pipes, 3 mM MgCl2, 1 mM EGTA, 15% glycerol, 1 mM PMSF, plus 0.5% Triton X-100) was 
performed for 10 minutes before fixation with paraformaldehyde. For RNase treatment, 
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previous to fixation, cells were treated with CSK buffer for 5 min at RT, and then treated with 
1 mg/ml RNase A in PBS for 10 min a RT. For immunodetection of nascent RNA, cells were 
pulsed with 2 mM 5-Fluorouridine for 1 hr, fixed in 1% paraformaldehyde in PBS and 
permeabilized in PBS containing 0.5% Triton X-100 for 5 min. Antibodies against 
halogenated UTP (anti-BrdU) were used to label nascent RNA. Glass slides were analyzed 
using a laser scan confocal microscope (Zeiss).  
 
BrdU incorporation assay 
Cells were pulsed with 30 µM bromodeoxyuridine (BrdU, Sigma) for 1 hr (tumor cells) or 3 
hr (fibroblasts). After pulsing, cells were fixed with 3% paraformaldehyde in PBS, 
permeabilized with 0.1% Triton X-100 in PBS, and RNA denatured with 50 mM NaOH for 
20 sec. BrdU incorporation was measured by immunofluorescence using an anti-BrdU 
antibody (GE Healthcare) and the nuclei were stained with Hoechst. Stained cells were 
visualized under a fluorescence microscope and at least 200 cells were scored for BrdU 
incorporation.  
 
Cell viability and flow cytometry 
Cells were harvested by trypsin treatment, permeabilized in 0.1% NP-40 in PBS containing 
RNase A (200 µg/ml) followed by Propidium Iodide (25 µg/ml) and/or Annexin V (Sigma) 
staining according to manufacturer’s instructions. Apoptosis scoring was performed by subG1 
determination or Annexin V staining. In both cases at least 10.000 cells were counted in 
independent experiments using a FACS (FACSCalibur, Becton-Dickinson). Cell viability was 
evaluated by a colorimetric assay using tetrazolium salt (MTT, Sigma) and reading 
absorbance at 550 nm on a multiwell scanning spectrophotometer after cell lysis with 33% 
DMF in SDS 30%. 
 
Chromatin immunoprecipitation 
Cells were crosslinked in 1% formaldehyde, washed in 125 mM glycine/PBS and harvested in 
Lysis Buffer (5 mM PIPES, 85 mM KCl, 0.5% NP-40). Pelleted cells were resuspended in 
RIPA-100 buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.5% 
Deoxycolate, 0.1% SDS). Sonicated chromatin (0.5Kb on average) (Bioruptor, Diagenode) 
was centrifugated. An aliquot of supernatant was used as input and the remainder was 
subjected to immunoprecipitation overnight at 4°C. Antibodies: for p53 immunoprecipitation 
a mix of PAb 240 and PAb 421 monoclonal antibodies, for HDAC3: anti-HDAC3 (Cell 
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Signaling), for Mage: a mix of affinity purified anti-Mage polyclonal antibodies, anti-MAGE 
monoclonal antibody (6C1) (Santa Cruz Biotechnology) and anti-Mage 57B monoclonal 
antibody, for Flag-tagged proteins: anti-Flag M2 monoclonal antibody (Sigma) and for Ac-
Histone H3: Anti-acetylated Histone H3 polyclonal antibody (Upstate Biotechnology). DNA-
protein complexes were recovered by 2 hr incubation with protein A/G PLUS-Agarose (Santa 
Cruz Biotechnology). Precipitates were extensively washed sequentially using RIPA-100 
buffer, RIPA-250 (as RIPA-100 but using 250 mM NaCl) and LiCl solution (10 mM Tris-HCl 
pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% deoxycolate, 0.5% NP-40). Samples were then 
subjected to RNAse A  treatment and decrosslinked overnight at 68°C in proteinase K 
solution (0.5% SDS, 100 mM NaCl, 150 ug/ml Prot-K). DNA was recovered by standard 
phenol-chloroform purification and sodium-acetate/ethanol precipitation. Quantitative PCR 
was performed on ABI PRISM 7000 PCR machine, using TaqMan Universal PCR Master 
Mix (Applied Biosystems). Primers and probes were obtained from Applied Biosystems and 
amplification settings were performed as described. 
 
In vitro acetylation/deacetylation assay 
500 ng of Histones (Sigma Chemical Co) were acetylated by incubating in acetylation buffer 
(50 mM TRIS-HCl pH7.5, 10% glycerol, 1 mM DTT) with 2ug of purified recombinant 
Histone Acetylase Transferase domain of p300 (GST-p300HAT) and 14C-AcetylCoA 
(Amersham) shaking for 1 hour at 30°C.  
Deacetylation assay was performed by incubating immunoprecipitated complex in 
deacetylation buffer (10 mM TRIS-HCl pH 8.0, 150 mM NaCl, 10% glycerol) with 200ng of 
14C-labeled histones, shaking for 16 hours at 30°C. Then, SDS-PAGE electrophoresis and 
autoradiography were performed for 14C-labeled histones detection. 
 
Analysis of SA-β-Galactosidase activity 
Cells were fixed in 0.5% glutaraldehyde in PBS/2 mM MgCl2 at pH 6.0 and then stained with 
staining solution containing 5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6 in PBS/2 mM MgCl2 at pH 
6.0 plus 1 mg/ml X-Gal, for 16 hr at 37°C. Cells were then washed extensively with H2O and 
observed under a bright field microscope.  
 
Immunoaffinity purification  
2x108 HeLa cells stably expressing HA-MageB2 were harvested in lysis buffer containing 50 
mM Tris-HCl pH 8.0, 5 mM EDTA, 150 mM NaCl, 0,5% NP-40 and Protease Inhibitor 
                                                                                                                 Materials and methods 
 - 101 -
Cocktail (Sigma). Lysates were precleared for 30 min with Protein A-Sepharose at 4°C and 
then incubated with prebound Protein A-sepharose to anti-HA monoclonal antibody (12CA5 
Roche) for 4 hr at 4°C. Beads were subsequently washed with SNNTE buffer containing 5% 
sucrose, 5 mM Tris-HCl pH 7.5, 5 mM EDTA, 200 mM NaCl, 1% NP-40 and Protease 
Inhibitor Cocktail. Immunoprecipitated complexes were resolved by SDS-PAGE and proteins 
visualized with colloidal blue coomassie. Bands then were isolated by in gel digestion and 
analyzed by mass spectrometry (Proteomic Facility at ICGEB, Trieste, Italy). 
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